BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270. [PMID: 17097848 DOI: 10.1016/j.ejso.2006.10.004] [Cited by in Crossref: 467] [Cited by in F6Publishing: 413] [Article Influence: 31.1] [Reference Citation Analysis]
Number Citing Articles
1 Winter K, Talar-Wojnarowska R, Dąbrowski A, Degowska M, Durlik M, Gąsiorowska A, Głuszek S, Jurkowska G, Kaczka A, Lampe P, Marek T, Nasierowska-Guttmejer A, Nowakowska-Duława E, Rydzewska G, Strzelczyk J, Śledziński Z, Małecka-Panas E. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Prz Gastroenterol 2019;14:1-18. [PMID: 30944673 DOI: 10.5114/pg.2019.83422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Tanase CP, Neagu M, Albulescu R, Codorean E, Dima SO. Biomarkers in the diagnosis and early detection of pancreatic cancer. Expert Opinion on Medical Diagnostics 2009;3:533-46. [DOI: 10.1517/17530050903117256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV;  NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713-1722. [PMID: 22241899 DOI: 10.1093/annonc/mdr561] [Cited by in Crossref: 148] [Cited by in F6Publishing: 130] [Article Influence: 16.4] [Reference Citation Analysis]
4 Qian L, Li Q, Baryeh K, Qiu W, Li K, Zhang J, Yu Q, Xu D, Liu W, Brand RE, Zhang X, Chen W, Liu G. Biosensors for early diagnosis of pancreatic cancer: a review. Transl Res 2019;213:67-89. [PMID: 31442419 DOI: 10.1016/j.trsl.2019.08.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 14.5] [Reference Citation Analysis]
5 Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K, Yano M. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010;251:461-9. [PMID: 20134315 DOI: 10.1097/SLA.0b013e3181cc90a3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
6 Udgata S, Takenaka N, Bamlet WR, Oberg AL, Yee SS, Carpenter EL, Herman D, Kim J, Petersen GM, Zaret KS. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement. Cancer Prev Res (Phila) 2021;14:223-32. [PMID: 33067248 DOI: 10.1158/1940-6207.CAPR-20-0403] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Chen J, Chen LJ, Yang RB, Xia YL, Zhou HC, Wu W, Lu Y, Hu LW, Zhao Y. Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma. Med Oncol. 2013;30:583. [PMID: 23609192 DOI: 10.1007/s12032-013-0583-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
8 Potjer TP, Mertens BJ, Nicolardi S, van der Burgt YE, Bonsing BA, Mesker WE, Tollenaar RA, Vasen HF. Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort. Transl Oncol 2016;9:242-7. [PMID: 27267843 DOI: 10.1016/j.tranon.2016.03.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
9 Luo G, Fan Z, Cheng H, Jin K, Guo M, Lu Y, Yang C, Fan K, Huang Q, Long J, Liu L, Xu J, Lu R, Ni Q, Warshaw AL, Liu C, Yu X. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology. 2018;18:971-976. [PMID: 30131287 DOI: 10.1016/j.pan.2018.08.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
10 Wang Z, Tian YP. Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma. Mol Clin Oncol 2014;2:265-8. [PMID: 24649344 DOI: 10.3892/mco.2013.226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
11 Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. J Proteome Res. 2012;11:1274-1283. [PMID: 22066465 DOI: 10.1021/pr200960u] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
12 Li J, Wang LJ, Ying X, Han SX, Bai E, Zhang Y, Zhu Q. Immunodiagnostic value of combined detection of autoantibodies to tumor-associated antigens as biomarkers in pancreatic cancer. Scand J Immunol 2012;75:342-9. [PMID: 22010875 DOI: 10.1111/j.1365-3083.2011.02657.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
13 Blaho M, Dítě P, Kunovský L, Kianička B. Autoimmune pancreatitis – An ongoing challenge. Advances in Medical Sciences 2020;65:403-8. [DOI: 10.1016/j.advms.2020.07.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Huang Y, Xu Y, Bi Y, Xu M, Lu J, Wang T, Li M, Chen Y, Liu Y, Huang F, Xu B, Zhang J, Wang W, Ning G. Relationship between CA 19-9 levels and glucose regulation in a middle-aged and elderly Chinese population: CA 19-9 levels and glucose regulation. Journal of Diabetes 2012;4:147-52. [DOI: 10.1111/j.1753-0407.2011.00179.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
15 Ercan Ş, Kaymaz Ö, Yücel N, Orçun A. Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study. Arch Gynecol Obstet 2012;285:579-84. [PMID: 21792548 DOI: 10.1007/s00404-011-2025-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
16 Martinez-Bosch N, Barranco LE, Orozco CA, Moreno M, Visa L, Iglesias M, Oldfield L, Neoptolemos JP, Greenhalf W, Earl J, Carrato A, Costello E, Navarro P. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Oncotarget 2018;9:32984-96. [PMID: 30250644 DOI: 10.18632/oncotarget.26034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
17 Goh TS, Ha M, Lee JS, Jeong DC, Jung ES, Han ME, Kim YH, Oh SO. Prognostic significance of EIF4G1 in patients with pancreatic ductal adenocarcinoma. Onco Targets Ther 2019;12:2853-9. [PMID: 31043796 DOI: 10.2147/OTT.S202101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
18 Efeovbokhan N, Makol A, Cuison RV, Minter RM, Kotaru VP, Conley BA, Chandana SR. An unusual case of autoimmune pancreatitis presenting as pancreatic mass and obstructive jaundice: a case report and review of the literature. J Med Case Reports. 2011;5:253. [PMID: 21714886 DOI: /10.1186/1752-1947-5-253] [Reference Citation Analysis]
19 Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, Valle JW, Dive C. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106:508-516. [PMID: 22187035 DOI: 10.1038/bjc.2011.545] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 16.4] [Reference Citation Analysis]
20 Chan A, Prassas I, Dimitromanolakis A, Brand RE, Serra S, Diamandis EP, Blasutig IM. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer. Clin Cancer Res. 2014;20:5787-5795. [PMID: 25239611 DOI: 10.1158/1078-0432.ccr-14-0289] [Cited by in Crossref: 75] [Cited by in F6Publishing: 43] [Article Influence: 10.7] [Reference Citation Analysis]
21 Serdarevic N. The Comparison Between Different Immunoassays for Serum Carbohydrate Antigen (CA 19-9) Concentration Measurement. Acta Inform Med 2018;26:235-9. [PMID: 30692705 DOI: 10.5455/aim.2018.26.235-239] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang ZY, Ding XQ, Zhu H, Wang RX, Pan XR, Tong JH. KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients. Front Oncol 2019;9:1295. [PMID: 31850201 DOI: 10.3389/fonc.2019.01295] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
23 Kim TH, Han SS, Park SJ, Lee WJ, Woo SM, Yoo T, Moon SH, Kim SH, Hong EK, Kim DY. CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81:e743-e748. [PMID: 21129857 DOI: 10.1016/j.ijrobp.2010.10.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
24 Dai X, Pang W, Zhou Y, Yao W, Xia L, Wang C, Chen X, Zen K, Zhang CY, Yuan Y. Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus. J Diabetes. 2016;8:422-433. [PMID: 25991015 DOI: 10.1111/1753-0407.12313] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
25 Hu Y, Zuo P, Ye BC. Label-free electrochemical impedance spectroscopy biosensor for direct detection of cancer cells based on the interaction between carbohydrate and lectin. Biosens Bioelectron 2013;43:79-83. [PMID: 23287651 DOI: 10.1016/j.bios.2012.11.028] [Cited by in Crossref: 73] [Cited by in F6Publishing: 53] [Article Influence: 8.1] [Reference Citation Analysis]
26 Riva F, Dronov OI, Khomenko DI, Huguet F, Louvet C, Mariani P, Stern MH, Lantz O, Proudhon C, Pierga JY. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Mol Oncol. 2016;10:481-493. [PMID: 26856794 DOI: 10.1016/j.molonc.2016.01.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 9.6] [Reference Citation Analysis]
27 Roesli C. Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact. Expert Review of Proteomics 2014;12:5-8. [DOI: 10.1586/14789450.2015.983478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Aggarwal G, Rabe KG, Petersen GM, Chari ST. New-onset diabetes in pancreatic cancer: a study in the primary care setting. Pancreatology 2012;12:156-61. [PMID: 22487526 DOI: 10.1016/j.pan.2012.02.003] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
29 Xu J, Cao Z, Liu W, You L, Zhou L, Wang C, Lou W, Sun B, Miao Y, Liu X, Zhang T, Zhao Y. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Annals of Surgery 2016;263:1173-9. [DOI: 10.1097/sla.0000000000001345] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 9.2] [Reference Citation Analysis]
30 Ong SL, Sachdeva A, Garcea G, Gravante G, Metcalfe MS, Lloyd DM, Berry DP, Dennison AR. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci. 2008;53:3213-3217. [PMID: 18465243 DOI: 10.1007/s10620-008-0289-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
31 Sun KD, Zhang YJ, Zhu LP, Yang B, Wang SY, Yu ZH, Zhang HC, Chen X. Abnormal serum carbohydrate antigen 19-9 levels in a patient with splenic retiform haemangioendothelioma concomitant with hepatic amyloidosis: A case report. World J Clin Cases 2020;8:1108-15. [PMID: 32258081 DOI: 10.12998/wjcc.v8.i6.1108] [Reference Citation Analysis]
32 Chan A, Diamandis EP, Blasutig IM. Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics 2013;81:126-34. [PMID: 23026552 DOI: 10.1016/j.jprot.2012.09.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
33 Velstra B, Bonsing BA, Mertens BJ, van der Burgt YE, Huijbers A, Vasen H, Mesker WE, Deelder AM, Tollenaar RA. Detection of pancreatic cancer using serum protein profiling. HPB (Oxford) 2013;15:602-10. [PMID: 23458426 DOI: 10.1111/hpb.12017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
34 Wiest NE, Moktan VP, Oman SP, Chirilă RM. Screening for pancreatic cancer: a review for general clinicians. Rom J Intern Med 2020;58:119-28. [PMID: 32364522 DOI: 10.2478/rjim-2020-0009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Roch AM, Mehrabi S, Krishnan A, Schmidt HE, Kesterson J, Beesley C, Dexter PR, Palakal M, Schmidt CM. Automated pancreatic cyst screening using natural language processing: a new tool in the early detection of pancreatic cancer. HPB (Oxford) 2015;17:447-53. [PMID: 25537257 DOI: 10.1111/hpb.12375] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
36 Caba O, Prados J, Ortiz R, Jiménez-Luna C, Melguizo C, Alvarez PJ, Delgado JR, Irigoyen A, Rojas I, Pérez-Florido J, Torres C, Perales S, Linares A, Aránega A. Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers. Dig Dis Sci 2014;59:2714-20. [PMID: 25069573 DOI: 10.1007/s10620-014-3291-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
37 Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, Zeh HJ, Grizzle WE, Huang Y, Lomakin A, Lokshin AE. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS One. 2014;9:e94928. [PMID: 24747429 DOI: 10.1371/journal.pone.0094928] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
38 Tanase CP. Caveolin-1: a marker for pancreatic cancer diagnosis. Expert Review of Molecular Diagnostics 2014;8:395-404. [DOI: 10.1586/14737159.8.4.395] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
39 Yin H, An M, So PK, Wong MY, Lubman DM, Yao Z. The analysis of alpha-1-antitrypsin glycosylation with direct LC-MS/MS. Electrophoresis 2018;39:2351-61. [PMID: 29405331 DOI: 10.1002/elps.201700426] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
40 Kaleta EJ, Tolan NV, Ness KA, O'Kane D, Algeciras-Schimnich A. CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation. Clin Biochem. 2013;46:814-818. [PMID: 23454392 DOI: 10.1016/j.clinbiochem.2013.02.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
41 Yakabe T, Nakafusa Y, Sumi K, Miyoshi A, Kitajima Y, Sato S, Noshiro H, Miyazaki K. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol. 2010;17:2349-2356. [PMID: 20217258 DOI: 10.1245/s10434-010-1004-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
42 Kim B, Lee K, Moon T, Kang P, Lee J, Kim J, Rhee J. How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? Digestive and Liver Disease 2009;41:364-9. [DOI: 10.1016/j.dld.2008.12.094] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
43 Le Large TYS, Meijer LL, Paleckyte R, Boyd LNC, Kok B, Wurdinger T, Schelfhorst T, Piersma SR, Pham TV, van Grieken NCT, Zonderhuis BM, Daams F, van Laarhoven HWM, Bijlsma MF, Jimenez CR, Giovannetti E, Kazemier G. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. Oncologist. 2020;25:e634-e643. [PMID: 31943574 DOI: 10.1634/theoncologist.2019-0680] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
44 Burns EA, Kasparian S, Khan U, Abdelrahim M. Pancreatic adenocarcinoma with early esophageal metastasis: A case report and review of literature. World J Clin Oncol 2020;11:83-90. [PMID: 32133277 DOI: 10.5306/wjco.v11.i2.83] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Liu Y, Kaur S, Huang Y, Fahrmann JF, Rinaudo JA, Hanash SM, Batra SK, Singhi AD, Brand RE, Maitra A, Haab BB. Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN. Cancer Epidemiol Biomarkers Prev 2020;29:2513-23. [PMID: 32532830 DOI: 10.1158/1055-9965.EPI-20-0161] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
46 Waanders E, van Keimpema L, Brouwer JT, van Oijen MG, Aerts R, Sweep FC, Nevens F, Drenth JP. Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver Int. 2009;29:1389-1395. [PMID: 19515221 DOI: 10.1111/j.1478-3231.2009.02055.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
47 Rückert F, Pilarsky C, Grützmann R. Serum tumor markers in pancreatic cancer-recent discoveries. Cancers (Basel) 2010;2:1107-24. [PMID: 24281109 DOI: 10.3390/cancers2021107] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
48 Sun B, Liu X, Gao Y, Li L, Dong Z. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients. British Journal of Biomedical Science 2016;73:152-7. [DOI: 10.1080/09674845.2016.1220706] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
49 Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 - tumor marker: Past, present, and future. World J Gastrointest Surg 2020;12:468-90. [PMID: 33437400 DOI: 10.4240/wjgs.v12.i12.468] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
50 Xiao PP, Wan QQ, Liao T, Tu JY, Zhang GJ, Sun ZY. Peptide Nucleic Acid-Functionalized Nanochannel Biosensor for the Highly Sensitive Detection of Tumor Exosomal MicroRNA. Anal Chem 2021;93:10966-73. [PMID: 34327982 DOI: 10.1021/acs.analchem.1c01898] [Reference Citation Analysis]
51 Tang Y, Cui Y, Zhang S, Zhang L. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection. Prog Mol Biol Transl Sci 2019;162:121-40. [PMID: 30905445 DOI: 10.1016/bs.pmbts.2019.01.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
52 Li TD, Zhang R, Chen H, Huang ZP, Ye X, Wang H, Deng AM, Kong JL. An ultrasensitive polydopamine bi-functionalized SERS immunoassay for exosome-based diagnosis and classification of pancreatic cancer. Chem Sci 2018;9:5372-82. [PMID: 30009009 DOI: 10.1039/c8sc01611a] [Cited by in Crossref: 86] [Cited by in F6Publishing: 21] [Article Influence: 28.7] [Reference Citation Analysis]
53 Okabayashi T, Nishimori I, Maeda H, Hanazaki K. Incidence of and predictive risk factors for intraductal papillary mucinous neoplasm of the pancreas with ordinary pancreatic cancer. J Clin Gastroenterol 2010;44:75-6. [PMID: 19564793 DOI: 10.1097/MCG.0b013e3181a15e65] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Halilovic E, Rasic I, Sofic A, Mujic A, Rovcanin A, Hodzic E, Kulovic E. The Importance of Determining Preoperative Serum Concentration of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen in Assessing the Progression of Colorectal Cancer. Med Arch 2020;74:346-9. [PMID: 33424087 DOI: 10.5455/medarh.2020.74.346-349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Gul K, Nas S, Ozdemir D, Gumus M, Ersoy R, Cakir B. CA 19-9 level in patients with type 2 diabetes mellitus and its relation to the metabolic control and microvascular complications. Am J Med Sci. 2011;341:28-32. [PMID: 21139492 DOI: 10.1097/MAJ.0b013e3181f0e2a0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
56 Kenner B, Chari ST, Kelsen D, Klimstra DS, Pandol SJ, Rosenthal M, Rustgi AK, Taylor JA, Yala A, Abul-Husn N, Andersen DK, Bernstein D, Brunak S, Canto MI, Eldar YC, Fishman EK, Fleshman J, Go VLW, Holt JM, Field B, Goldberg A, Hoos W, Iacobuzio-Donahue C, Li D, Lidgard G, Maitra A, Matrisian LM, Poblete S, Rothschild L, Sander C, Schwartz LH, Shalit U, Srivastava S, Wolpin B. Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. Pancreas 2021;50:251-79. [PMID: 33835956 DOI: 10.1097/MPA.0000000000001762] [Reference Citation Analysis]
57 Pang Y, Holmes MV, Chen Z, Kartsonaki C. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 2019;34:330-45. [PMID: 30550622 DOI: 10.1111/jgh.14576] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
58 Frampton AE, Fletcher CE, Gall TM, Castellano L, Bevan CL, Stebbing J, Krell J. Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer. Expert Rev Mol Diagn. 2013;13:425-430. [PMID: 23782250 DOI: 10.1586/erm.13.31] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
59 Princivalle A, Monasta L, Butturini G, Bassi C, Perbellini L. Pancreatic ductal adenocarcinoma can be detected by analysis of volatile organic compounds (VOCs) in alveolar air. BMC Cancer. 2018;18:529. [PMID: 29728093 DOI: 10.1186/s12885-018-4452-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
60 Dong D, Jia L, Zhang L, Ma N, Zhang A, Zhou Y, Ren L. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer. Cancer Sci. 2018;109:2841-2851. [PMID: 29945294 DOI: 10.1111/cas.13712] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
61 Luo G, Jin K, Cheng H, Liu C, Guo M, Lu Y, Yang C, Xu J, Wang W, Gao H. Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncol Lett. 2017;14:6795-6800. [PMID: 29163700 DOI: 10.3892/ol.2017.7071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
62 Goh SK, Gold G, Christophi C, Muralidharan V. Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ J Surg. 2017;87:987-992. [PMID: 28803454 DOI: 10.1111/ans.14131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
63 Pavlou MP, Diamandis EP, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. Clin Chem. 2013;59:147-157. [PMID: 23019307 DOI: 10.1373/clinchem.2012.184614] [Cited by in Crossref: 93] [Cited by in F6Publishing: 75] [Article Influence: 10.3] [Reference Citation Analysis]
64 Borazanci E, Sckolnik S, Amini A. Neo-adjuvant therapy for pancreatic cancer: hope for the future. Expert Rev Gastroenterol Hepatol 2019;13:579-89. [PMID: 30979348 DOI: 10.1080/17474124.2019.1607294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
65 Heinzman Z, Schmidt C, Sliwinski MK, Goonesekere NCW. The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer. Pharmaceuticals (Basel) 2021;14:209. [PMID: 33802396 DOI: 10.3390/ph14030209] [Reference Citation Analysis]
66 Efeovbokhan N, Makol A, Cuison RV, Minter RM, Kotaru VP, Conley BA, Chandana SR. An unusual case of autoimmune pancreatitis presenting as pancreatic mass and obstructive jaundice: a case report and review of the literature. J Med Case Rep 2011;5:253. [PMID: 21714886 DOI: 10.1186/1752-1947-5-253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
67 Grayson K, Gregory E, Khan G, Guinn BA. Urine Biomarkers for the Early Detection of Ovarian Cancer - Are We There Yet? Biomark Cancer 2019;11:1179299X19830977. [PMID: 30833816 DOI: 10.1177/1179299X19830977] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
68 Meijer LL, Garajová I, Caparello C, Le Large TYS, Frampton AE, Vasile E, Funel N, Kazemier G, Giovannetti E. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Ann Surg 2020;271:1137-47. [PMID: 30394883 DOI: 10.1097/SLA.0000000000003084] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
69 Al-Fatlawi A, Malekian N, García S, Henschel A, Kim I, Dahl A, Jahnke B, Bailey P, Bolz SN, Poetsch AR, Mahler S, Grützmann R, Pilarsky C, Schroeder M. Deep Learning Improves Pancreatic Cancer Diagnosis Using RNA-Based Variants. Cancers (Basel) 2021;13:2654. [PMID: 34071263 DOI: 10.3390/cancers13112654] [Reference Citation Analysis]
70 Kanaan N, Goffin E, Pirson Y, Devuyst O, Hassoun Z. Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2010;55:916-922. [PMID: 20189277 DOI: 10.1053/j.ajkd.2009.12.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
71 Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level.Korean J Fam Med. 2019;40:314-322. [PMID: 30959581 DOI: 10.4082/kjfm.18.0057] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
72 Mattila N, Seppänen H, Mustonen H, Przybyla B, Haglund C, Lassila R. Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma. Clin Appl Thromb Hemost 2018;24:1267-75. [PMID: 29865859 DOI: 10.1177/1076029618779133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
73 Honda K, Srivastava S. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. Biomark Med 2016;10:1197-207. [PMID: 27673558 DOI: 10.2217/bmm-2016-0209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
74 Hogendorf P, Skulimowski A, Durczyński A, Kumor A, Poznańska G, Oleśna A, Rut J, Strzelczyk J. A Panel of CA19-9, Ca125, and Ca15-3 as the Enhanced Test for the Differential Diagnosis of the Pancreatic Lesion. Dis Markers 2017;2017:8629712. [PMID: 28356610 DOI: 10.1155/2017/8629712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
75 Pang Y, Wang C, Lu L, Wang C, Sun Z, Xiao R. Dual-SERS biosensor for one-step detection of microRNAs in exosome and residual plasma of blood samples for diagnosing pancreatic cancer. Biosensors and Bioelectronics 2019;130:204-13. [DOI: 10.1016/j.bios.2019.01.039] [Cited by in Crossref: 97] [Cited by in F6Publishing: 69] [Article Influence: 48.5] [Reference Citation Analysis]
76 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 25.0] [Reference Citation Analysis]
77 Navaneethan U, Lourdusamy V, Poptic E, Hammel JP, Sanaka MR, Parsi MA. Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures. Dig Dis Sci 2015;60:903-9. [PMID: 25344422 DOI: 10.1007/s10620-014-3397-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
78 Karpathakis A, Pericleous M, Luong TV, Khoo B, Thirlwell C, Toumpanakis C, Caplin ME. Pancreatic adenocarcinoma in a patient with multiple endocrine neoplasia 1 syndrome. Pancreas 2013;42:725-6. [PMID: 23591436 DOI: 10.1097/MPA.0b013e31827591e9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
79 Sclafani F, Iyer R, Cunningham D, Starling N. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Crit Rev Oncol Hematol 2015;95:318-36. [PMID: 25921418 DOI: 10.1016/j.critrevonc.2015.03.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
80 Asbun HJ, Conlon K, Fernandez-cruz L, Friess H, Shrikhande SV, Adham M, Bassi C, Bockhorn M, Büchler M, Charnley RM, Dervenis C, Fingerhutt A, Gouma DJ, Hartwig W, Imrie C, Izbicki JR, Lillemoe KD, Milicevic M, Montorsi M, Neoptolemos JP, Sandberg AA, Sarr M, Vollmer C, Yeo CJ, Traverso LW. When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery. Surgery 2014;155:887-92. [DOI: 10.1016/j.surg.2013.12.032] [Cited by in Crossref: 78] [Cited by in F6Publishing: 49] [Article Influence: 11.1] [Reference Citation Analysis]
81 Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013;10:607-620. [PMID: 23856888 DOI: 10.1038/nrgastro.2013.120] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 17.9] [Reference Citation Analysis]
82 Regel I, Mayerle J, Mahajan UM. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer. Cancers (Basel) 2020;12:E1024. [PMID: 32326341 DOI: 10.3390/cancers12041024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
83 Xiong H, Huang Z, Yang Z, Lin Q, Yang B, Fang X, Liu B, Chen H, Kong J. Recent Progress in Detection and Profiling of Cancer Cell-Derived Exosomes. Small 2021;17:e2007971. [PMID: 34075696 DOI: 10.1002/smll.202007971] [Reference Citation Analysis]
84 Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 2008;12:1422-8. [PMID: 18543046 DOI: 10.1007/s11605-008-0554-3] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 6.5] [Reference Citation Analysis]
85 Welinsky S, Lucas AL. Familial Pancreatic Cancer and the Future of Directed Screening. Gut Liver 2017;11:761-70. [PMID: 28609837 DOI: 10.5009/gnl16414] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
86 Goonesekere NC, Wang X, Ludwig L, Guda C. A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLoS One 2014;9:e93046. [PMID: 24740004 DOI: 10.1371/journal.pone.0093046] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
87 Chen J, Liu Q, Ling Y, Yang H, Wen J, Luo K, Hu Y, Tan Z, Fu J. Extraordinarily elevated serum CA19-9 in a patient with posterior mediastinum cyst: a case report. Clin Chem Lab Med. 2017;55:e279-e281. [PMID: 28672729 DOI: 10.1515/cclm-2017-0001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 You L, Ma L, Zhao W, Zhao Y, Dai M. Emerging role of tumor markers and biochemistry in the preoperative invasive assessment of intraductal papillary mucinous neoplasm of the pancreas. Clinica Chimica Acta 2016;454:89-93. [DOI: 10.1016/j.cca.2015.12.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
89 Velstra B, Vonk MA, Bonsing BA, Mertens BJ, Nicolardi S, Huijbers A, Vasen H, Deelder AM, Mesker WE, van der Burgt YEM, Tollenaar RAEM. Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques. J Cancer Res Clin Oncol 2015;141:531-41. [DOI: 10.1007/s00432-014-1812-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
90 Karaman K, Bostanci EB, Aksoy E, Kurt M, Celep B, Ulas M, Dalgic T, Surmelioglu A, Hayran M, Akoglu M. The predictive value of mean platelet volume in differential diagnosis of non-functional pancreatic neuroendocrine tumors from pancreatic adenocarcinomas. Eur J Intern Med. 2011;22:e95-e98. [PMID: 22075321 DOI: 10.1016/j.ejim.2011.04.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
91 McDowell CT, Lu X, Mehta AS, Angel PM, Drake RR. Applications and continued evolution of glycan imaging mass spectrometry. Mass Spectrom Rev 2021. [PMID: 34392557 DOI: 10.1002/mas.21725] [Reference Citation Analysis]
92 Wang L, Shan J, Feng F, Ma Z. Novel redox species polyaniline derivative-Au/Pt as sensing platform for label-free electrochemical immunoassay of carbohydrate antigen 199. Anal Chim Acta 2016;911:108-13. [PMID: 26893092 DOI: 10.1016/j.aca.2016.01.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
93 Uygur-Bayramicli O, Dabak R, Orbay E, Dolapcioglu C, Sargin M, Kilicoglu G, Guleryuzlu Y, Mayadagli A. Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol 2007;13:5357-9. [PMID: 17879406 DOI: 10.3748/wjg.v13.i40.5357] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
94 Shi J, Lew M, Zalupski MM, Roh MH, Kwon RS, Pang JC. Implication of Suspicious Cytology in Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Pancreatic Cancer. J Gastrointest Canc 2015;46:54-9. [DOI: 10.1007/s12029-014-9681-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
95 Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 2011;56:2491-2496. [PMID: 21516323 DOI: 10.1007/s10620-011-1709-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
96 Martinez-Useros J, Georgiev-Hristov T, Borrero-Palacios A, Fernandez-Aceñero MJ, Rodríguez-Remírez M, Del Puerto-Nevado L, Cebrian A, Gomez Del Pulgar MT, Cazorla A, Vega-Bravo R, Perez N, Celdran A, Garcia-Foncillas J. Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 "STARD Compliant". Medicine (Baltimore) 2015;94:e1972. [PMID: 26559273 DOI: 10.1097/MD.0000000000001972] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
97 Qiu J, Yang G, Feng M, Zheng S, Cao Z, You L, Zheng L, Zhang T, Zhao Y. Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Mol Cancer. 2018;17:2. [PMID: 29304816 DOI: 10.1186/s12943-017-0755-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
98 Zhang H, Zhu M, Du Y, Zhang H, Zhang Q, Liu Q, Huang Z, Zhang L, Li H, Xu L, Zhou X, Zhu W, Shu Y, Liu P. A Panel of 12-lncRNA Signature Predicts Survival of Pancreatic Adenocarcinoma. J Cancer 2019;10:1550-9. [PMID: 31031865 DOI: 10.7150/jca.27823] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
99 Ansari D, Andersson R, Bauden MP, Andersson B, Connolly JB, Welinder C, Sasor A, Marko-Varga G. Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. J Cancer Res Clin Oncol. 2015;141:369-380. [PMID: 25216700 DOI: 10.1007/s00432-014-1817-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
100 Bergquist JR, Puig CA, Shubert CR, Groeschl RT, Habermann EB, Kendrick ML, Nagorney DM, Smoot RL, Farnell MB, Truty MJ. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. Journal of the American College of Surgeons 2016;223:52-65. [DOI: 10.1016/j.jamcollsurg.2016.02.009] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 15.4] [Reference Citation Analysis]
101 Vandenbrouck Y, Christiany D, Combes F, Loux V, Brun V. Bioinformatics Tools and Workflow to Select Blood Biomarkers for Early Cancer Diagnosis: An Application to Pancreatic Cancer. Proteomics 2019;19:1800489. [DOI: 10.1002/pmic.201800489] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
102 La Greca G, Sofia M, Lombardo R, Latteri S, Ricotta A, Puleo S, Russello D. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein. World J Gastroenterol 2012;18:4150-5. [PMID: 22919247 DOI: 10.3748/wjg.v18.i31.4150] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
103 Turanli B, Yildirim E, Gulfidan G, Arga KY, Sinha R. Current State of "Omics" Biomarkers in Pancreatic Cancer. J Pers Med 2021;11:127. [PMID: 33672926 DOI: 10.3390/jpm11020127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
104 Dimastromatteo J, Houghton JL, Lewis JS, Kelly KA. Challenges of Pancreatic Cancer. Cancer J. 2015;21:188-193. [PMID: 26049698 DOI: 10.1097/ppo.0000000000000109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
105 Farrán A, Cai C, Sandoval M, Xu Y, Liu J, Hernáiz MJ, Linhardt RJ. Green solvents in carbohydrate chemistry: from raw materials to fine chemicals. Chem Rev 2015;115:6811-53. [PMID: 26121409 DOI: 10.1021/cr500719h] [Cited by in Crossref: 198] [Cited by in F6Publishing: 87] [Article Influence: 33.0] [Reference Citation Analysis]
106 Chang JC, Kundranda M. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. Int J Mol Sci. 2017;18. [PMID: 28335509 DOI: 10.3390/ijms18030667] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 13.5] [Reference Citation Analysis]
107 Rho JH, Mead JR, Wright WS, Brenner DE, Stave JW, Gildersleeve JC, Lampe PD. Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J Proteomics 2014;96:291-9. [PMID: 24185138 DOI: 10.1016/j.jprot.2013.10.030] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
108 Isaksson S, Jönsson P, Monsef N, Brunnström H, Bendahl PO, Jönsson M, Staaf J, Planck M. CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. PLoS One 2017;12:e0186284. [PMID: 29049328 DOI: 10.1371/journal.pone.0186284] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
109 Castellanos JA, Merchant NB. Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol 2014;21:747-51. [PMID: 24092447 DOI: 10.1245/s10434-013-3289-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
110 Yang C, Liu Z, Zeng X, Wu Q, Liao X, Wang X, Han C, Yu T, Zhu G, Qin W, Peng T. Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma. Aging (Albany NY). 2019;11:3679-3703. [PMID: 31182680 DOI: 10.18632/aging.102007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
111 Dong Q, Ma Y, Zhang Y, Qu X, Li Z, Qi Y, Liu Y, Li C, Li K, Yang X, Che X. Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma. Oncotarget 2017;8:57163-73. [PMID: 28915662 DOI: 10.18632/oncotarget.18714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
112 Zhuge X, Guo C, Chen Y, Feng L, Jia R, Zhao Y, Sun K, Wang Z, Chen X. The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma. Pancreas 2018;47:1290-5. [DOI: 10.1097/mpa.0000000000001181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
113 Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algül H, Friess H, Janssen KP, König A, Ghadimi M, Gallmeier E, Bartsch DK, Geissler M, Staib L, Tannapfel A, Kleger A, Beutel A, Schulte LA, Kornmann M, Ettrich TJ, Seufferlein T. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Theranostics 2019;9:1280-7. [PMID: 30867830 DOI: 10.7150/thno.29247] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
114 Kudelka MR, Stowell SR, Cummings RD, Neish AS. Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD. Nat Rev Gastroenterol Hepatol. 2020;17:597-617. [PMID: 32710014 DOI: 10.1038/s41575-020-0331-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
115 Le Calvez-Kelm F, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P, Pertesi M, Fabianova E, Adamcakova Z, Holcatova I. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget. 2016;7:78827-78840. [PMID: 27705932 DOI: 10.18632/oncotarget.12386] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 15.0] [Reference Citation Analysis]
116 Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg 2009;33:716-22. [PMID: 19082654 DOI: 10.1007/s00268-008-9853-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
117 Morrison M. Pancreatic cancer and diabetes. Adv Exp Med Biol 2012;771:229-39. [PMID: 23393682 DOI: 10.1007/978-1-4614-5441-0_18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
118 Chiang AJ, Chen J, Chung YC, Huang HJ, Liou WS, Chang C. A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer. J Gynecol Oncol 2014;25:51-7. [PMID: 24459581 DOI: 10.3802/jgo.2014.25.1.51] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
119 Ravi K, Sanchez W, Sweetser S. Primary pancreatic follicular lymphoma mimicking adenocarcinoma. Clin Gastroenterol Hepatol 2010;8:e101-2. [PMID: 20580941 DOI: 10.1016/j.cgh.2010.05.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
120 Hakomori SI, Cummings RD. Glycosylation effects on cancer development. Glycoconj J 2012;29:565-6. [PMID: 22996057 DOI: 10.1007/s10719-012-9448-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
121 Chen DW, Fan YF, Li J, Jiang XX. MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma. Tumour Biol. 2013;34:1553-1557. [PMID: 23400716 DOI: 10.1007/s13277-013-0685-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
122 Hinton J, Callan R, Bodine C, Glasgow W, Brower S, Jiang S, Li J. Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas. Expert Review of Molecular Diagnostics 2014;13:431-43. [DOI: 10.1586/erm.13.38] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
123 Bauden M, Pamart D, Ansari D, Herzog M, Eccleston M, Micallef J, Andersson B, Andersson R. Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. Clin Epigenetics 2015;7:106. [PMID: 26451166 DOI: 10.1186/s13148-015-0139-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
124 De Marchi G, Paiella S, Luchini C, Capelli P, Bassi C, Frulloni L. Very high serum levels of CA 19-9 in autoimmune pancreatitis: Report of four cases and brief review of literature. J Dig Dis 2016;17:697-702. [PMID: 27579898 DOI: 10.1111/1751-2980.12403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
125 Zhang Y, Qiu L, Wang Y, Qin X, Li Z. High-throughput and high-sensitivity quantitative analysis of serum unsaturated fatty acids by chip-based nanoelectrospray ionization-Fourier transform ion cyclotron resonance mass spectrometry: early stage diagnostic biomarkers of pancreatic cancer. Analyst 2014;139:1697-706. [PMID: 24551873 DOI: 10.1039/c3an02130k] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
126 Chang YT, Wu CC, Shyr YM, Chen TC, Hwang TL, Yeh TS, Chang KP, Liu HP, Liu YL, Tsai MH, Chang YS, Yu JS. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One. 2011;6:e20029. [PMID: 21625447 DOI: 10.1371/journal.pone.0020029] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
127 Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10:473-510. [PMID: 25621663 DOI: 10.1146/annurev-pathol-012414-040438] [Cited by in Crossref: 360] [Cited by in F6Publishing: 309] [Article Influence: 60.0] [Reference Citation Analysis]
128 Chen Z, Sangwan V, Banerjee S, Mackenzie T, Dudeja V, Li X, Wang H, Vickers SM, Saluja AK. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Mol Cancer 2013;12:105. [PMID: 24025188 DOI: 10.1186/1476-4598-12-105] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
129 Haab BB, Huang Y, Balasenthil S, Partyka K, Tang H, Anderson M, Allen P, Sasson A, Zeh H, Kaul K, Kletter D, Ge S, Bern M, Kwon R, Blasutig I, Srivastava S, Frazier ML, Sen S, Hollingsworth MA, Rinaudo JA, Killary AM, Brand RE. Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. PLoS One 2015;10:e0139049. [PMID: 26431551 DOI: 10.1371/journal.pone.0139049] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
130 Kim K, Yong SH, Lee SH, Lee SH, Leem AY, Kim SY, Chung K, Kim EY, Jung JY, Park MS, Kim YS, Lee HJ, Kang YA. Correlation between serum carbohydrate antigen 19-9 levels and computed tomography severity score in patients with nontuberculous mycobacterial pulmonary disease. Sci Rep 2021;11:2777. [PMID: 33531571 DOI: 10.1038/s41598-021-82363-5] [Reference Citation Analysis]
131 Wang H, Gao X, Ma Z. Multifunctional substrate of label-free electrochemical immunosensor for ultrasensitive detection of cytokeratins antigen 21-1. Sci Rep 2017;7:1023. [PMID: 28432339 DOI: 10.1038/s41598-017-01250-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
132 Ho J, Li X, Zhang L, Liang Y, Hu W, Yau JCW, Chan H, Gin T, Chan MTV, Tse G, Wu WKK. Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset. Semin Cancer Biol 2019;55:70-7. [PMID: 29705685 DOI: 10.1016/j.semcancer.2018.04.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
133 Pandiaraja J, Viswanathan S, Antomy TB, Thirumuruganand S, Kumaresan DS. The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas. J Clin Diagn Res 2016;10:PC06-9. [PMID: 27134925 DOI: 10.7860/JCDR/2016/17106.7398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
134 Hackbarth JS, Murata K, Reilly WM, Algeciras-schimnich A. Performance of CEA and CA19-9 in identifying pleural effusions caused by specific malignancies. Clinical Biochemistry 2010;43:1051-5. [DOI: 10.1016/j.clinbiochem.2010.05.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
135 Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13:340-351. [PMID: 23331006 DOI: 10.2174/1566524011313030003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 90] [Article Influence: 2.4] [Reference Citation Analysis]
136 Tonack S, Aspinall-O'Dea M, Jenkins RE, Elliot V, Murray S, Lane CS, Kitteringham NR, Neoptolemos JP, Costello E. A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J Proteomics 2009;73:352-6. [PMID: 19651253 DOI: 10.1016/j.jprot.2009.07.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
137 Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1148-1154. [PMID: 18760544 DOI: 10.1016/j.ijrobp.2008.06.1483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
138 Kozman MA, Fisher OM, Rebolledo BJ, Valle SJ, Alzahrani N, Liauw W, Morris DL. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy. European Journal of Surgical Oncology 2017;43:2299-307. [DOI: 10.1016/j.ejso.2017.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
139 Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol. 2015;21:3157-3165. [PMID: 25805920 DOI: 10.3748/wjg.v21.i11.3157] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 72] [Article Influence: 14.0] [Reference Citation Analysis]
140 Liu P, Zhu Y, Liu L. Elevated serum CA72-4 levels predict poor prognosis in pancreatic adenocarcinoma after intensity-modulated radiation therapy. Oncotarget 2015;6:9592-9. [PMID: 25860937 DOI: 10.18632/oncotarget.3562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
141 Wang X, Li Y, Tian H, Qi J, Li M, Fu C, Wu F, Wang Y, Cheng D, Zhao W, Zhang C, Wang T, Rao J, Zhang W. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma. BMC Cancer. 2014;14:578. [PMID: 25106741 DOI: 10.1186/1471-2407-14-578] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
142 Zhang J, Huang T, Zhang F, Xu J, Chen G, Wang X, Huang L, Peng Z. Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma. Tumour Biol 2015;36:2257-61. [PMID: 25787748 DOI: 10.1007/s13277-014-2435-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
143 Wen Z, Si A, Yang J, Yang P, Yang X, Liu H, Yan X, Li W, Zhang B. Elevation of CA19-9 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma. HPB (Oxford). 2017;19:951-956. [PMID: 28750922 DOI: 10.1016/j.hpb.2017.06.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
144 Martinez-Useros J, Georgiev-Hristov T, Fernández-Aceñero MJ, Borrero-Palacios A, Indacochea A, Guerrero S, Li W, Cebrián A, Gómez Del Pulgar T, Puime-Otin A, Del Puerto-Nevado L, Rodríguez-Remírez M, Pérez N, Celdrán A, Gebauer F, Garcia-Foncillas J. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. PLoS One 2017;12:e0182044. [PMID: 28763470 DOI: 10.1371/journal.pone.0182044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
145 Cervoni GE, Cheng JJ, Stackhouse KA, Heimburg-Molinaro J, Cummings RD. O-glycan recognition and function in mice and human cancers. Biochem J 2020;477:1541-64. [PMID: 32348475 DOI: 10.1042/BCJ20180103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
146 Itoi T, Sugimoto M, Umeda J, Sofuni A, Tsuchiya T, Tsuji S, Tanaka R, Tonozuka R, Honjo M, Moriyasu F, Kasuya K, Nagakawa Y, Abe Y, Takano K, Kawachi S, Shimazu M, Soga T, Tomita M, Sunamura M. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination. Int J Mol Sci 2017;18:E767. [PMID: 28375170 DOI: 10.3390/ijms18040767] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
147 de la Poza Gómez G, Rivero Fernández M, Vázquez Romero M, Angueira Lapeña T, Arranz de la Mata G, Boixeda de Miquel D. Síndrome constitucional asociado a hepatotoxicidad por metformina. Gastroenterología y Hepatología 2008;31:643-5. [DOI: 10.1016/s0210-5705(08)75812-6] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
148 Wu L, Wang Y, Xu X, Liu Y, Lin B, Zhang M, Zhang J, Wan S, Yang C, Tan W. Aptamer-Based Detection of Circulating Targets for Precision Medicine. Chem Rev 2021. [PMID: 33667075 DOI: 10.1021/acs.chemrev.0c01140] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
149 Sandblom G, Granroth S, Rasmussen IC. TPS, CA 19-9, VEGF-A, and CEA as diagnostic and prognostic factors in patients with mass lesions in the pancreatic head. Ups J Med Sci. 2008;113:57-64. [PMID: 18521799 DOI: 10.3109/2000-1967-214] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
150 Kunovsky L, Tesarikova P, Kala Z, Kroupa R, Kysela P, Dolina J, Trna J. The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer. Can J Gastroenterol Hepatol 2018;2018:5389820. [PMID: 30186820 DOI: 10.1155/2018/5389820] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
151 Sze KC, Pirola RC, Apte MV, Wilson JS. Current options for the diagnosis of chronic pancreatitis. Expert Rev Mol Diagn. 2014;14:199-215. [PMID: 24512138 DOI: 10.1586/14737159.2014.883277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
152 O'Neill RS, Stoita A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol 2021;27:4045-87. [PMID: 34326612 DOI: 10.3748/wjg.v27.i26.4045] [Reference Citation Analysis]
153 Wu H, Chen X, Ji J, Zhou R, Liu J, Ni W, Qu L, Ni H, Ni R, Bao B, Xiao M. Progress of Exosomes in the Diagnosis and Treatment of Pancreatic Cancer. Genet Test Mol Biomarkers 2019;23:215-22. [PMID: 30793953 DOI: 10.1089/gtmb.2018.0235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
154 Lu S, Ahmed T, Du P, Wang Y. Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. Int J Mol Sci 2017;18:E1201. [PMID: 28587243 DOI: 10.3390/ijms18061201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
155 Wu X, Zhang ZX, Chen XY, Xu YL, Yin N, Yang J, Zhu DM, Li DC, Zhou J. A Panel of Three Biomarkers Identified by iTRAQ for the Early Diagnosis of Pancreatic Cancer. Proteomics Clin Appl 2019;13:e1800195. [PMID: 31025496 DOI: 10.1002/prca.201800195] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
156 Kosanam H, Prassas I, Chrystoja CC, Soleas I, Chan A, Dimitromanolakis A, Blasutig IM, Rückert F, Gruetzmann R, Pilarsky C. Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol Cell Proteomics. 2013;12:2820-2832. [PMID: 23798558 DOI: 10.1074/mcp.m112.023507] [Cited by in Crossref: 68] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
157 Szász AM, Győrffy B, Marko-Varga G. Cancer heterogeneity determined by functional proteomics. Semin Cell Dev Biol 2017;64:132-42. [PMID: 27569188 DOI: 10.1016/j.semcdb.2016.08.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
158 Bhat K, Wang F, Ma Q, Li Q, Mallik S, Hsieh TC, Wu E. Advances in biomarker research for pancreatic cancer. Curr Pharm Des 2012;18:2439-51. [PMID: 22372502 DOI: 10.2174/13816128112092439] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
159 Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12:1929-1946. [PMID: 27246628 DOI: 10.2217/fon-2016-0010] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 21.2] [Reference Citation Analysis]
160 Margel D, Bostrom P, Baniel J, Yossepowitch O, Zlotta A, Fleshner N. External Validation of a Biomarker Based Pre-Cystectomy Algorithm to Predict Nonorgan Confined Urothelial Cancers. Journal of Urology 2012;187:840-4. [DOI: 10.1016/j.juro.2011.10.148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
161 Farina A, Dumonceau JM, Frossard JL, Hadengue A, Hochstrasser DF, Lescuyer P. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J Proteome Res. 2009;8:159-169. [PMID: 19055478 DOI: 10.1021/pr8004925] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
162 Farina A, Delhaye M, Lescuyer P, Dumonceau JM. Bile proteome in health and disease. Compr Physiol 2014;4:91-108. [PMID: 24692135 DOI: 10.1002/cphy.c130016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
163 Majumder S, Chari ST, Ahlquist DA. Molecular detection of pancreatic neoplasia: Current status and future promise. World J Gastroenterol. 2015;21:11387-11395. [PMID: 26526068 DOI: 10.3748/wjg.v21.i40.11387] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
164 Unger K, Mehta KY, Kaur P, Wang Y, Menon SS, Jain SK, Moonjelly RA, Suman S, Datta K, Singh R, Fogel P, Cheema AK. Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma. Oncotarget. 2018;9:23078-23090. [PMID: 29796173 DOI: 10.18632/oncotarget.25212] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
165 Yang Y, Yan S, Tian H, Bao Y. Macrophage inhibitory cytokine-1 vs carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies. Medicine (Baltimore). 2018;97:e9994. [PMID: 29489701 DOI: 10.1097/md.0000000000009994] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
166 Yue T, Partyka K, Maupin KA, Hurley M, Andrews P, Kaul K, Moser AJ, Zeh H, Brand RE, Haab BB. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics. 2011;11:3665-3674. [PMID: 21751362 DOI: 10.1002/pmic.201000827] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
167 Sperti C, Friziero A, Serafini S, Bissoli S, Ponzoni A, Grego A, Grego E, Moletta L. Prognostic Implications of 18-FDG Positron Emission Tomography/Computed Tomography in Resectable Pancreatic Cancer. J Clin Med 2020;9:E2169. [PMID: 32659933 DOI: 10.3390/jcm9072169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
168 Yang WC, Liao SY, Phan TL, Hieu NV, Chu PY, Yi CC, Wu HJ, Chang KM, Ching CT. An Immunosensor for the Detection of ULBP2 Biomarker. Micromachines (Basel) 2020;11:E568. [PMID: 32503144 DOI: 10.3390/mi11060568] [Reference Citation Analysis]
169 Tonini V, Zanni M. Pancreatic cancer in 2021: What you need to know to win. WJG 2021;27:5851-89. [DOI: 10.3748/wjg.v27.i35.5851] [Reference Citation Analysis]
170 Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, Verheij J, Meijer SL, Dijk F, Bijlsma MF, van Oijen MGH, van Laarhoven HWM. Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis. Biochim Biophys Acta Rev Cancer. 2017;1868:394-403. [PMID: 28801248 DOI: 10.1016/j.bbcan.2017.08.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
171 Tshering G, Dorji PW, Chaijaroenkul W, Na-Bangchang K. Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review. Am J Trop Med Hyg. 2018;98:1788-1797. [PMID: 29637880 DOI: 10.4269/ajtmh.17-0879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
172 Rodrigues JG, Balmaña M, Macedo JA, Poças J, Fernandes Â, de-Freitas-Junior JCM, Pinho SS, Gomes J, Magalhães A, Gomes C, Mereiter S, Reis CA. Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. Cellular Immunology 2018;333:46-57. [DOI: 10.1016/j.cellimm.2018.03.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 56] [Article Influence: 22.0] [Reference Citation Analysis]
173 Bowlus CL, Olson KA, Gershwin ME. Evaluation of indeterminate biliary strictures. Nat Rev Gastroenterol Hepatol. 2016;13:28-37. [PMID: 26526122 DOI: 10.1038/nrgastro.2015.182] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
174 Singh S, Pal K, Yadav J, Tang H, Partyka K, Kletter D, Hsueh P, Ensink E, Kc B, Hostetter G, Xu HE, Bern M, Smith DF, Mehta AS, Brand R, Melcher K, Haab BB. Upregulation of glycans containing 3' fucose in a subset of pancreatic cancers uncovered using fusion-tagged lectins. J Proteome Res 2015;14:2594-605. [PMID: 25938165 DOI: 10.1021/acs.jproteome.5b00142] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
175 Giannis D, Moris D, Barbas AS. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians. Cancers (Basel) 2021;13:1071. [PMID: 33802340 DOI: 10.3390/cancers13051071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
176 Tran TB, Norton JA, Ethun CG, Pawlik TM, Buettner S, Schmidt C, Beal EW, Hawkins WG, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Idrees K, Isom CA, Hatzaras I, Shenoy R, Maithel SK, Poultsides GA. Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable? J Gastrointest Surg 2017;21:1245-53. [PMID: 28497252 DOI: 10.1007/s11605-017-3440-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
177 Ansari D, Torén W, Zhou Q, Hu D, Andersson R. Proteomic and genomic profiling of pancreatic cancer. Cell Biol Toxicol 2019;35:333-43. [PMID: 30771135 DOI: 10.1007/s10565-019-09465-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
178 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.ssn.2078-6891.2011.021] [Reference Citation Analysis]
179 Chen Z, Sangwan V, Banerjee S, Chugh R, Dudeja V, Vickers SM, Saluja AK. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Cancer Lett 2014;348:156-66. [PMID: 24662747 DOI: 10.1016/j.canlet.2014.03.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
180 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.1002/ijc.20037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
181 Crawley AS, O'Kennedy RJ. The need for effective pancreatic cancer detection and management: a biomarker-based strategy. Expert Rev Mol Diagn 2015;15:1339-53. [PMID: 26394703 DOI: 10.1586/14737159.2015.1083862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
182 Ohgi K, Okamura Y, Yamamoto Y, Ashida R, Ito T, Sugiura T, Aramaki T, Uesaka K. Perioperative Computed Tomography Assessments of the Pancreas Predict Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy. Medicine (Baltimore) 2016;95:e2535. [PMID: 26871772 DOI: 10.1097/MD.0000000000002535] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
183 Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019;13:410. [PMID: 31044028 DOI: 10.4081/oncol.2019.410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 19.5] [Reference Citation Analysis]
184 Zhang J, Wang Y, Zhao T, Li Y, Tian L, Zhao J, Zhang J. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer. World J Surg Oncol 2020;18:31. [PMID: 32028958 DOI: 10.1186/s12957-020-1809-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
185 Lopes Vendrami C, Shin JS, Hammond NA, Kothari K, Mittal PK, Miller FH. Differentiation of focal autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Abdom Radiol 2020;45:1371-86. [DOI: 10.1007/s00261-019-02210-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
186 Jin X, Wu Y. Diagnostic utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels. Afr Health Sci 2015;15:123-30. [PMID: 25834540 DOI: 10.4314/ahs.v15i1.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
187 Krishna SG, Li F, Bhattacharya A, Ladha H, Porter K, Singh A, Ross WA, Bhutani MS, Lee JH. Differentiation of pancreatic ductal adenocarcinoma from other neoplastic solid pancreatic lesions: a tertiary oncology center experience. Gastrointest Endosc 2015;81:370-9. [PMID: 25442085 DOI: 10.1016/j.gie.2014.08.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
188 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol. 2014;20:11142-11159. [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 63] [Article Influence: 12.3] [Reference Citation Analysis]
189 Barreto SG. Pancreatic Cancer. In: Barreto SG, Windsor JA, editors. Surgical Diseases of the Pancreas and Biliary Tree. Singapore: Springer; 2018. pp. 427-69. [DOI: 10.1007/978-981-10-8755-4_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
190 Krishna SG, Bhattacharya A, Li F, Ross WA, Ladha H, Porter K, Atiq M, Bhutani MS, Lee JH. Diagnostic Differentiation of Pancreatic Neuroendocrine Tumor From Other Neoplastic Solid Pancreatic Lesions During Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Pancreas. 2016;45:394-400. [PMID: 26418912 DOI: 10.1097/MPA.0000000000000488] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
191 Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ. Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med. 2009;47:750-754. [PMID: 19402792 DOI: 10.1515/cclm.2009.152] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
192 Yamada T, Nakanishi Y, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, Tanaka K, Kurashima Y, Ebihara Y, Murakami S, Shichinohe T, Mitsuhashi T, Hirano S. Impact of serum carbohydrate antigen 19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma: Preoperative s-CA19-9 level in ICC. Journal of Gastroenterology and Hepatology 2018;33:1626-33. [DOI: 10.1111/jgh.14124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
193 Meleady P, Abdul Rahman R, Henry M, Moriarty M, Clynes M. Proteomic analysis of pancreatic ductal adenocarcinoma. Expert Rev Proteomics 2020;17:453-67. [PMID: 32755290 DOI: 10.1080/14789450.2020.1803743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
194 Xu M, Sethi A. Diagnosing Biliary Malignancy. Gastrointestinal Endoscopy Clinics of North America 2015;25:677-90. [DOI: 10.1016/j.giec.2015.06.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
195 Partyka K, Maupin KA, Brand RE, Haab BB. Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics 2012;12:2212-20. [PMID: 22623153 DOI: 10.1002/pmic.201100676] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
196 Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol. 2011;2:88-100. [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 96] [Article Influence: 12.2] [Reference Citation Analysis]
197 Farina A, Dumonceau JM, Lescuyer P. Proteomic analysis of human bile and potential applications for cancer diagnosis. Expert Rev Proteomics. 2009;6:285-301. [PMID: 19489700 DOI: 10.1586/epr.09.12] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
198 Kuzmanov U, Kosanam H, Diamandis EP. The sweet and sour of serological glycoprotein tumor biomarker quantification. BMC Med. 2013;11:31. [PMID: 23390961 DOI: 10.1186/1741-7015-11-31] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
199 Kim JY, Kim SH, Kim SY. Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT. Eur Radiol 2014;24:2435-48. [PMID: 25113646 DOI: 10.1007/s00330-014-3262-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
200 Hu D, Ansari D, Pawłowski K, Zhou Q, Sasor A, Welinder C, Kristl T, Bauden M, Rezeli M, Jiang Y, Marko-Varga G, Andersson R. Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma. Oncotarget 2018;9:9789-807. [PMID: 29515771 DOI: 10.18632/oncotarget.23929] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
201 Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, Hanash SM. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 2008;5:e123. [PMID: 18547137 DOI: 10.1371/journal.pmed.0050123] [Cited by in Crossref: 195] [Cited by in F6Publishing: 169] [Article Influence: 15.0] [Reference Citation Analysis]
202 Martinez-Useros J, Garcia-Foncillas J. Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? Biomed Res Int 2016;2016:4873089. [PMID: 27689078 DOI: 10.1155/2016/4873089] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
203 Ren AH, Prassas I, Soosaipillai A, Jarvi S, Gallinger S, Kulasingam V, Diamandis EP. Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden. F1000Res 2020;9:732. [PMID: 33274048 DOI: 10.12688/f1000research.24654.2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Rajesh S, Cox MJ, Runau F. Molecular advances in pancreatic cancer: A genomic, proteomic and metabolomic approach. WJG 2021;27:5171-80. [DOI: 10.3748/wjg.v27.i31.5171] [Reference Citation Analysis]
205 Staal B, Liu Y, Barnett D, Hsueh P, He Z, Gao C, Partyka K, Hurd MW, Singhi AD, Drake RR, Huang Y, Maitra A, Brand RE, Haab BB. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis. Clin Cancer Res. 2019;25:2745-2754. [PMID: 30617132 DOI: 10.1158/1078-0432.ccr-18-3310] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
206 Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, Park JY. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013;54:643-649. [PMID: 23549809 DOI: 10.3349/ymj.2013.54.3.643] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
207 Jiang K, Tan E, Sayegh Z, Centeno B, Malafa M, Coppola D. Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma. Appl Immunohistochem Mol Morphol. 2016; Epub ahead of print. [PMID: 27093451 DOI: 10.1097/pai.0000000000000368] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
208 Dutta SK, Girotra M, Singla M, Dutta A, Otis Stephen F, Nair PP, Merchant NB. Serum HSP70: a novel biomarker for early detection of pancreatic cancer. Pancreas 2012;41:530-4. [PMID: 22158074 DOI: 10.1097/MPA.0b013e3182374ace] [Cited by in Crossref: 48] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
209 Choe JW, Kim HJ, Kim JS, Cha J, Joo MK, Lee BJ, Park J, Bak Y. Usefulness of CA 19–9 for pancreatic cancer screening in patients with new-onset diabetes. Hepatobiliary & Pancreatic Diseases International 2018;17:263-8. [DOI: 10.1016/j.hbpd.2018.04.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
210 Ferri MJ, Saez M, Figueras J, Fort E, Sabat M, López-Ben S, de Llorens R, Aleixandre RN, Peracaula R. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology. PLoS One 2016;11:e0147214. [PMID: 26808421 DOI: 10.1371/journal.pone.0147214] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
211 Sivaraman A, Muthukrishnan A, Boopathy Senguttvan N, Anil Suchak S, Kannan U. Predictors of malignancy in pancreatic head mass: a prospective study. Pan Afr Med J 2011;9:30. [PMID: 22145063 DOI: 10.4314/pamj.v9i1.71206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
212 Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, Nicolini A, Topolcan O, Heinemann V. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441-447. [PMID: 19690057 DOI: 10.1093/annonc/mdp332] [Cited by in Crossref: 207] [Cited by in F6Publishing: 181] [Article Influence: 17.3] [Reference Citation Analysis]
213 Yu Y, Tong Y, Zhong A, Wang Y, Lu R, Guo L. Identification of Serum microRNA-25 as a novel biomarker for pancreatic cancer. Medicine (Baltimore). 2020;99:e23863. [PMID: 33350781 DOI: 10.1097/md.0000000000023863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
214 Vasiliades G, Kopanakis N, Vasiloglou M, Zografos G, Margaris H, Masselou K, Kokosi E, Liakakos T. Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer. Int J Biol Markers 2012;27:e186-94. [PMID: 22865301 DOI: 10.5301/JBM.2012.9348] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
215 Uozumi N, Gao C, Yoshioka T, Nakano M, Moriwaki K, Nakagawa T, Masuda T, Tanabe M, Miyoshi E. Identification of a novel type of CA19-9 carrier in human bile and sera of cancer patients: an implication of the involvement in nonsecretory exocytosis. J Proteome Res 2010;9:6345-53. [PMID: 20954701 DOI: 10.1021/pr100600u] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
216 Brychta N, Krahn T, von Ahsen O. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer. Clin Chem 2016;62:1482-91. [PMID: 27591291 DOI: 10.1373/clinchem.2016.257469] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 12.2] [Reference Citation Analysis]
217 Łukaszewicz-Zając M, Gryko M, Mroczko B. The role of selected chemokines and their specific receptors in pancreatic cancer. Int J Biol Markers 2018;33:141-7. [PMID: 29799354 DOI: 10.1177/1724600817753094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
218 Tessitore A, Gaggiano A, Cicciarelli G, Verzella D, Capece D, Fischietti M, Zazzeroni F, Alesse E. Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int J Proteomics 2013;2013:125858. [PMID: 23401773 DOI: 10.1155/2013/125858] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
219 Delgado JA, Ballesteros MA, Parera MM, Bauça JM. Pancreatic Cancer Insights: Optimization of the Diagnostic Capacity of Tumor Biomarkers. Lab Med 2021:lmab016. [PMID: 33900408 DOI: 10.1093/labmed/lmab016] [Reference Citation Analysis]
220 Motoi F, Rikiyama T, Katayose Y, Egawa S, Unno M. Retrospective Evaluation of the Influence of Postoperative Tumor Marker Status on Survival and Patterns of Recurrence After Surgery for Pancreatic Cancer Based on RECIST Guidelines. Ann Surg Oncol 2011;18:371-9. [DOI: 10.1245/s10434-010-1311-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
221 Mirus JE, Zhang Y, Li CI, Lokshin AE, Prentice RL, Hingorani SR, Lampe PD. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. Clin Cancer Res. 2015;21:1764-1771. [PMID: 25589628 DOI: 10.1158/1078-0432.ccr-13-3474] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
222 Huerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervelló C, Garcés-Albir M, Cervantes A, Ibarrola-Villava M. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Cancers (Basel) 2021;13:994. [PMID: 33673558 DOI: 10.3390/cancers13050994] [Reference Citation Analysis]
223 Tanţău A, Leucuţa DC, Tanţău M, Boţan E, Zaharie R, Mândruţiu A, Tomuleasa IC. Inflammation, Tumoral Markers and Interleukin-17, -10, and -6 Profiles in Pancreatic Adenocarcinoma and Chronic Pancreatitis. Dig Dis Sci 2021;66:3427-38. [PMID: 33184795 DOI: 10.1007/s10620-020-06700-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
224 Taniuchi K, Tsuboi M, Sakaguchi M, Saibara T. Measurement of serum PODXL concentration for detection of pancreatic cancer. Onco Targets Ther 2018;11:1433-45. [PMID: 29588598 DOI: 10.2147/OTT.S155367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
225 Suenaga Y, Kanda M, Ito S, Mochizuki Y, Teramoto H, Ishigure K, Murai T, Asada T, Ishiyama A, Matsushita H, Tanaka C, Kobayashi D, Fujiwara M, Murotani K, Kodera Y. Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. World J Gastrointest Oncol. 2019;11:17-27. [PMID: 30984347 DOI: 10.4251/wjgo.v11.i1.17] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
226 Usón Junior PLS, Callegaro-Filho D, Bugano DDG, Moura F, Maluf FC. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. J Gastrointest Cancer 2018;49:481-6. [PMID: 28924968 DOI: 10.1007/s12029-017-0007-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
227 Ansari D, Aronsson L, Sasor A, Welinder C, Rezeli M, Marko-Varga G, Andersson R. The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science. J Transl Med. 2014;12:87. [PMID: 24708694 DOI: 10.1186/1479-5876-12-87] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
228 Sudsarn P, Boonmars T, Ruangjirachuporn W, Namwat N, Loilome W, Sriraj P, Aukkanimart R, Nadchanan W, Jiraporn S. Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma. Pathol Oncol Res 2016;22:57-65. [DOI: 10.1007/s12253-015-9967-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
229 Li L, Yue GG, Fung KP, Leung PC, Lau CB, Leung PS. Establishment of an orthotopic model of pancreatic cancer to evaluate the antitumor effects of irinotecan through the biomarker carbohydrate antigen 19-9 in mice. Pancreas 2014;43:1126-8. [PMID: 25207664 DOI: 10.1097/MPA.0000000000000183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
230 Luo G, Jin K, Guo M, Cheng H, Liu Z, Xiao Z, Lu Y, Long J, Liu L, Xu J, Liu C, Gao Y, Ni Q, Yu X. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Oncol Lett 2017;13:881-6. [PMID: 28356973 DOI: 10.3892/ol.2016.5501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
231 Sun X, Liu M, Hao J, Li D, Luo Y, Wang X, Yang Y, Li F, Shui W, Chen Q, Zhou J. Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle 2013;12:1133-41. [PMID: 23470638 DOI: 10.4161/cc.24215] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
232 Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, Elton E, Arnoletti JP, Christein JD, Vickers SM, Langmead CJ, Landsittel DP, Whitcomb DC, Grizzle WE, Lokshin AE. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res. 2011;17:805-816. [PMID: 21325298 DOI: 10.1158/1078-0432.ccr-10-0248] [Cited by in Crossref: 148] [Cited by in F6Publishing: 97] [Article Influence: 14.8] [Reference Citation Analysis]
233 Matsuda S, Yoshimura H, Kondo S, Sano K. Temporomandibular dislocation caused by pancreatic cancer metastasis: A case report. Oncol Lett 2017;14:6053-8. [PMID: 29113245 DOI: 10.3892/ol.2017.6951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
234 Zhou B, Xu JW, Cheng YG, Gao JY, Hu SY, Wang L, Zhan HX. Early detection of pancreatic cancer: Where are we now and where are we going? Int J Cancer. 2017;141:231-241. [PMID: 28240774 DOI: 10.1002/ijc.30670] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 19.8] [Reference Citation Analysis]
235 Wang X, Wang C, Zhang H. Improvement of Diagnostic Accuracy for Pancreatic Cancer with Serum Lactate Dehydrogenase. Cancer Manag Res 2021;13:4879-86. [PMID: 34188541 DOI: 10.2147/CMAR.S312312] [Reference Citation Analysis]
236 Kim SH, Shin KH, Moon SH, Jang J, Kim HS, Suh JS, Yang WI. Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. Cancer Med 2017;6:1311-22. [PMID: 28493412 DOI: 10.1002/cam4.1022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
237 Maier A, Plaza-heck P, Meixner F, Guenther F, Kaufmann BA, Kramer M, Heidt T, Zirlik A, Hilgendorf I, Reinöhl J, Stachon P, Bronsert P, Birkemeyer R, Neudorfer I, Peter K, Bode C, von zur Mühlen C. A molecular intravascular ultrasound contrast agent allows detection of activated platelets on the surface of symptomatic human plaques. Atherosclerosis 2017;267:68-77. [DOI: 10.1016/j.atherosclerosis.2017.10.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
238 Shimodaira M, Niwa T, Nakajima K, Kobayashi M, Hanyu N, Nakayama T. The relation between CA 19-9 level and early-phase insulin secretion in normoglycemic and prediabetic subjects. Int J Biol Markers 2015;30:e169-73. [PMID: 25588858 DOI: 10.5301/jbm.5000130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
239 Tanase CP, Neagu M, Albulescu R, Hinescu ME. Advances in pancreatic cancer detection. Adv Clin Chem. 2010;51:145-180. [PMID: 20857621 DOI: 10.1016/s0065-2423(10)51006-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
240 Martinez-useros J, Li W, Georgiev-hristov T, Fernandez-aceñero MJ, Borrero-palacios A, Perez N, Celdran A, Garcia-foncillas J. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients. Pathol Oncol Res 2019;25:269-78. [DOI: 10.1007/s12253-017-0341-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
241 Oliveira C, Calmeiro J, Carrascal MA, Falcão A, Gomes C, Miguel Neves B, Teresa Cruz M. Exosomes as new therapeutic vectors for pancreatic cancer treatment. Eur J Pharm Biopharm 2021;161:4-14. [PMID: 33561524 DOI: 10.1016/j.ejpb.2021.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Houg DS, Bijlsma MF. The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma. Mol Cancer. 2018;17:95. [PMID: 29903049 DOI: 10.1186/s12943-018-0842-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
243 Hernandez YG, Lucas AL. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol 2016;8:18-29. [PMID: 26798434 DOI: 10.4251/wjgo.v8.i1.18] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
244 Tang H, Singh S, Partyka K, Kletter D, Hsueh P, Yadav J, Ensink E, Bern M, Hostetter G, Hartman D, Huang Y, Brand RE, Haab BB. Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A. Mol Cell Proteomics. 2015;14:1323-1333. [PMID: 25733690 DOI: 10.1074/mcp.m114.047837] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
245 Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuño FM, Guillen-Ponce C, Rojas I, Aranda E, Torres C, Prados J. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. PLoS One 2018;13:e0194844. [PMID: 29617451 DOI: 10.1371/journal.pone.0194844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
246 Miglani RK, Bhateja N, Bhat RS, Kumar KV. Diagnostic Role of Platelet Lymphocyte Ratio(PLR) in Pancreatic Head Masses. Indian J Surg 2013;75:4-9. [PMID: 24426375 DOI: 10.1007/s12262-012-0443-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
247 Pils S, Paternostro C, Mayerhoefer ME, Reinthaller A, Feichtinger M. Heavy black tea consumption and elevated CA 19-9 and CA 125 levels. A case report on a patient with ovarian endometriotic cysts. Gynecological Endocrinology 2019;35:478-80. [DOI: 10.1080/09513590.2018.1564743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
248 Tanase CP, Dima S, Mihai M, Raducan E, Nicolescu MI, Albulescu L, Voiculescu B, Dumitrascu T, Cruceru LM, Leabu M, Popescu I, Hinescu ME. Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma. J Mol Hist 2009;40:23-9. [DOI: 10.1007/s10735-008-9209-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
249 Zeng P, Li H, Chen Y, Pei H, Zhang L. Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases. Prog Mol Biol Transl Sci. 2019;162:253-264. [PMID: 30905455 DOI: 10.1016/bs.pmbts.2018.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
250 Lin C, Zhao GC, Xu YD, Wang DS, Jin DY, Ji Y, Lou WH, Wu WC. Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Oncotarget 2016;7:60657-64. [PMID: 27447976 DOI: 10.18632/oncotarget.10630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
251 Chang C, Chen P, Wang S, Hsu S, Hsu W, Tsai C, Wadekar PV, Puttaswamy S, Cheng K, Hsieh S, Wang HJ, Kuo K, Sun Y, Tu L. Fast detection of tumor marker CA 19-9 using AlGaN/GaN high electron mobility transistors. Sensors and Actuators B: Chemical 2018;267:191-7. [DOI: 10.1016/j.snb.2018.04.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
252 Coté GA, Sherman S. Biliary Stricture and Negative Cytology: What Next? Clinical Gastroenterology and Hepatology 2011;9:739-43. [DOI: 10.1016/j.cgh.2011.04.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
253 Zhang G, He F, Zhao G, Huang Z, Li X, Xia X, Guo Y, Xu W, Xiong S, Ma Y, Zheng M, Liu W. Combining Serum DNA Methylation Biomarkers and Protein Tumor Markers Improved Clinical Sensitivity for Early Detection of Colorectal Cancer. Int J Genomics 2021;2021:6613987. [PMID: 33977101 DOI: 10.1155/2021/6613987] [Reference Citation Analysis]
254 Hui L, Rixv L, Xiuying Z. A system for tumor heterogeneity evaluation and diagnosis based on tumor markers measured routinely in the laboratory. Clinical Biochemistry 2015;48:1241-5. [DOI: 10.1016/j.clinbiochem.2015.07.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
255 Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017;109:djw266. [PMID: 28376157 DOI: 10.1093/jnci/djw266] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
256 Shin K, Jung EK, Park SJ, Jeong S, Kim IH, Lee MA. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy. World J Gastrointest Oncol 2021;13:915-28. [PMID: 34457195 DOI: 10.4251/wjgo.v13.i8.915] [Reference Citation Analysis]
257 Chen J, Chen LJ, Xia YL, Zhou HC, Yang RB, Wu W, Lu Y, Hu LW, Zhao Y. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2013;139:1117-1127. [PMID: 23546595 DOI: 10.1007/s00432-013-1422-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
258 Li C, Wang X, Casal I, Wang J, Li P, Zhang W, Xu E, Lai M, Zhang H. Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer. J Cell Mol Med 2016;20:1420-6. [PMID: 26990020 DOI: 10.1111/jcmm.12830] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
259 Kim SH, Lee MJ, Hwang HK, Lee SH, Kim H, Paik Y, Kang CM. Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study. CBM 2019;24:335-42. [DOI: 10.3233/cbm-181847] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
260 Su Q, Zhu EC, Qu YL, Wang DY, Qu WW, Zhang CG, Wu T, Gao ZH. Serum level of co-expressed hub miRNAs as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma. J Cancer 2018;9:3991-9. [PMID: 30410604 DOI: 10.7150/jca.27697] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
261 Chapman CG, Waxman I. Portal-vein blood samples as a new diagnostic entity for pancreatic cancer. Expert Rev Gastroenterol Hepatol 2016;10:665-7. [PMID: 27077275 DOI: 10.1080/17474124.2016.1176911] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
262 Martinez NS, Trindade AJ, Sejpal DV. Determining the Indeterminate Biliary Stricture: Cholangioscopy and Beyond. Curr Gastroenterol Rep 2020;22:58. [PMID: 33141356 DOI: 10.1007/s11894-020-00797-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
263 Navaglia F, Fogar P, Basso D, Greco E, Padoan A, Tonidandel L, Fadi E, Zambon CF, Bozzato D, Moz S, Seraglia R, Pedrazzoli S, Plebani M. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med. 2009;47:713-723. [PMID: 19426140 DOI: 10.1515/cclm.2009.158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
264 Zhang Q, Chen S, Zeng L, Chen Y, Lian G, Qian C, Li J, Xie R, Huang KH. New developments in the early diagnosis of pancreatic cancer. Expert Rev Gastroenterol Hepatol 2017;11:149-56. [PMID: 27937041 DOI: 10.1080/17474124.2017.1271323] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
265 Lee DH, Jang JY, Kang JS, Kim JR, Han Y, Kim E, Kwon W, Kim SW. Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data. Ann Hepatobiliary Pancreat Surg 2018;22:386-96. [PMID: 30588531 DOI: 10.14701/ahbps.2018.22.4.386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
266 Kim D, Zhu H, Nassri A, Mokdad A, Kukreja S, Polanco P, Huerta S, Ramzan Z. Survival analysis of veteran patients with pancreatic cancer. J Dig Dis. 2016;17:399-407. [PMID: 27235863 DOI: 10.1111/1751-2980.12361] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
267 Yue T, Maupin KA, Fallon B, Li L, Partyka K, Anderson MA, Brenner DE, Kaul K, Zeh H, Moser AJ, Simeone DM, Feng Z, Brand RE, Haab BB. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One. 2011;6:e29180. [PMID: 22220206 DOI: 10.1371/journal.pone.0029180] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
268 Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol. 2011;17:867-897. [PMID: 21412497 DOI: 10.3748/wjg.v17.i7.867] [Cited by in CrossRef: 114] [Cited by in F6Publishing: 99] [Article Influence: 11.4] [Reference Citation Analysis]
269 Rho JH, Ladd JJ, Li CI, Potter JD, Zhang Y, Shelley D, Shibata D, Coppola D, Yamada H, Toyoda H, Tada T, Kumada T, Brenner DE, Hanash SM, Lampe PD. Protein and glycomic plasma markers for early detection of adenoma and colon cancer. Gut. 2018;67:473-484. [PMID: 27821646 DOI: 10.1136/gutjnl-2016-312794] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
270 Tavano F, Fontana A, Mazza T, Gioffreda D, Biagini T, Palumbo O, Carella M, Andriulli A. Early-Onset Diabetes as Risk Factor for Pancreatic Cancer: miRNA Expression Profiling in Plasma Uncovers a Role for miR-20b-5p, miR-29a, and miR-18a-5p in Diabetes of Recent Diagnosis. Front Oncol 2020;10:1567. [PMID: 33072549 DOI: 10.3389/fonc.2020.01567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
271 Herreros-Villanueva M, Gironella M, Castells A, Bujanda L. Molecular markers in pancreatic cancer diagnosis. Clin Chim Acta. 2013;418:22-29. [PMID: 23305796 DOI: 10.1016/j.cca.2012.12.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
272 Wu L, Guo W, Li Y, Cheng T, Yao Y, Zhang Y, Liu B, Zhong M, Li S, Deng X, Zhu W. [Value of endoscopic ultrasound-guided fine needle aspiration in pretest prediction and diagnosis of pancreatic ductal adenocarcinoma]. Nan Fang Yi Ke Da Xue Xue Bao. 2018;38:1171-1178. [PMID: 30377133 DOI: 10.3969/j.issn.1673-4254.2018.10.04] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
273 Giovinazzo F, Turri G, Zanini S, Butturini G, Scarpa A, Bassi C. Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma. Surg Oncol. 2012;21:e171-e182. [PMID: 22981281 DOI: 10.1016/j.suronc.2012.07.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
274 Prassas I, Chrystoja CC, Makawita S, Diamandis EP. Bioinformatic identification of proteins with tissue-specific expression for biomarker discovery. BMC Med 2012;10:39. [PMID: 22515324 DOI: 10.1186/1741-7015-10-39] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
275 Zhang X, Ke H, Wang Z, Guo W, Zhang A, Huang C, Jia N. An ultrasensitive multi-walled carbon nanotube–platinum–luminol nanocomposite-based electrochemiluminescence immunosensor. Analyst 2017;142:2253-60. [DOI: 10.1039/c7an00417f] [Cited by in Crossref: 27] [Cited by in F6Publishing: 2] [Article Influence: 6.8] [Reference Citation Analysis]
276 Shahangian S, Alspach TD, Astles JR, Yesupriya A, Dettwyler WK. Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010. Arch Pathol Lab Med 2014;138:189-203. [PMID: 23738761 DOI: 10.5858/arpa.2013-0149-OA] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
277 Galli C, Basso D, Plebani M. CA 19-9: handle with care. Clin Chem Lab Med. 2013;51:1369-1383. [PMID: 23370912 DOI: 10.1515/cclm-2012-0744] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 6.9] [Reference Citation Analysis]
278 Turrini O, Schmidt CM, Moreno J, Parikh P, Matos JM, House MG, Zyromski NJ, Nakeeb A, Pitt HA, Lillemoe KD. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy? J Gastrointest Surg 2009;13:1791-7. [PMID: 19459018 DOI: 10.1007/s11605-009-0916-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
279 Sancho-Albero M, Sebastián V, Sesé J, Pazo-Cid R, Mendoza G, Arruebo M, Martín-Duque P, Santamaría J. Isolation of exosomes from whole blood by a new microfluidic device: proof of concept application in the diagnosis and monitoring of pancreatic cancer. J Nanobiotechnology 2020;18:150. [PMID: 33092584 DOI: 10.1186/s12951-020-00701-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
280 Fallon BP, Curnutte B, Maupin KA, Partyka K, Choi S, Brand RE, Langmead CJ, Tembe W, Haab BB. The Marker State Space (MSS) method for classifying clinical samples. PLoS One 2013;8:e65905. [PMID: 23750276 DOI: 10.1371/journal.pone.0065905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
281 Brychta N, Drosch M, Driemel C, Fischer JC, Neves RP, Esposito I, Knoefel W, Möhlendick B, Hille C, Stresemann A, Krahn T, Kassack MU, Stoecklein NH, von Ahsen O. Isolation of circulating tumor cells from pancreatic cancer by automated filtration. Oncotarget 2017;8:86143-56. [PMID: 29156783 DOI: 10.18632/oncotarget.21026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
282 Xue A, Scarlett CJ, Chung L, Butturini G, Scarpa A, Gandy R, Wilson SR, Baxter RC, Smith RC. Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer 2010;103:391-400. [PMID: 20588270 DOI: 10.1038/sj.bjc.6605764] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
283 Zhang P, Zou M, Wen X, Gu F, Li J, Liu G, Dong J, Deng X, Gao J, Li X, Jia X, Dong Z, Chen L, Wang Y, Tian Y. Development of serum parameters panels for the early detection of pancreatic cancer. Int J Cancer. 2014;134:2646-2655. [PMID: 24615168 DOI: 10.1002/ijc.28584] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
284 Zhang S, Chen Y, Zhu Z, Ding Y, Ren S, Zuo Y. Differential expression of carbohydrate antigen 19-9 in human colorectal cancer: A comparison with colon and rectal cancers. Mol Clin Oncol 2013;1:1072-8. [PMID: 24649295 DOI: 10.3892/mco.2013.173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
285 Habartová L, Bunganič B, Tatarkovič M, Zavoral M, Vondroušová J, Syslová K, Setnička V. Chiroptical spectroscopy and metabolomics for blood-based sensing of pancreatic cancer. Chirality 2018;30:581-91. [DOI: 10.1002/chir.22834] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
286 Song ZG, Hao JH, Gao S, Gao CT, Tang Y, Liu JC. The outcome of cryoablation in treating advanced pancreatic cancer: a comparison with palliative bypass surgery alone. J Dig Dis. 2014;15:561-569. [PMID: 24958092 DOI: 10.1111/1751-2980.12170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
287 Tomita A, Mori M, Hiwatari K, Yamaguchi E, Itoi T, Sunamura M, Soga T, Tomita M, Sugimoto M. Effect of storage conditions on salivary polyamines quantified via liquid chromatography-mass spectrometry. Sci Rep 2018;8:12075. [PMID: 30104641 DOI: 10.1038/s41598-018-30482-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
288 Zhang X, Nie H, Whited J, Wang D, Li Y, Sun XL. Recent approaches for directly profiling cell surface sialoform. Glycobiology 2018;28:910-24. [PMID: 29800278 DOI: 10.1093/glycob/cwy046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
289 McConnell YJ, Farshidfar F, Weljie AM, Kopciuk KA, Dixon E, Ball CG, Sutherland FR, Vogel HJ, Bathe OF. Distinguishing Benign from Malignant Pancreatic and Periampullary Lesions Using Combined Use of ¹H-NMR Spectroscopy and Gas Chromatography-Mass Spectrometry. Metabolites 2017;7:E3. [PMID: 28098776 DOI: 10.3390/metabo7010003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
290 Zhang ZM, Wang JS, Zulfiqar H, Lv H, Dao FY, Lin H. Early Diagnosis of Pancreatic Ductal Adenocarcinoma by Combining Relative Expression Orderings With Machine-Learning Method. Front Cell Dev Biol 2020;8:582864. [PMID: 33178697 DOI: 10.3389/fcell.2020.582864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
291 Distler M, Pilarsky E, Kersting S, Grützmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Int J Surg. 2013;11:1067-1072. [PMID: 24161419 DOI: 10.1016/j.ijsu.2013.10.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
292 Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, Marsh T, Sanada M, Sasajima Y, Nakamori S, Shimahara M, Ueno T, Tsuchida A, Sata N, Ioka T, Yasunami Y, Kosuge T, Miura N, Kamita M, Sakamoto T, Shoji H, Jung G, Srivastava S, Yamada T. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Sci Rep. 2015;5:15921. [PMID: 26549697 DOI: 10.1038/srep15921] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
293 Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73-85. [PMID: 26830752 DOI: 10.1016/s0140-6736(16)00141-0] [Cited by in Crossref: 995] [Cited by in F6Publishing: 579] [Article Influence: 199.0] [Reference Citation Analysis]
294 Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG, Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol. 2017;111:152-165. [PMID: 28259290 DOI: 10.1016/j.critrevonc.2017.01.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
295 Li L, Zhang GQ, Chen H, Zhao ZJ, Chen HZ, Liu H, Wang G, Jia YH, Pan SH, Kong R, Wang YW, Sun B. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Oncotarget. 2016;7:71773-71781. [PMID: 27708234 DOI: 10.18632/oncotarget.12365] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
296 Kim YJ, Koh HK, Chie EK, Oh DY, Bang YJ, Nam EM, Kim K. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy. Int J Clin Oncol 2017;22:1069-75. [PMID: 28477059 DOI: 10.1007/s10147-017-1129-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
297 Jaworski JJ, Morgan RD, Sivakumar S. Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer. Cancers (Basel) 2020;12:E3704. [PMID: 33317202 DOI: 10.3390/cancers12123704] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
298 Zhou G, Liu X, Wang X, Jin D, Chen Y, Li G, Li C, Fu D, Xu W, Wang X. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort. Onco Targets Ther 2017;10:1199-206. [PMID: 28280354 DOI: 10.2147/OTT.S116136] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
299 Kim MS, Jeon TJ, Park JY, Choi J, Shin WC, Park SE, Seo JY, Kim YM. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease. Korean J Gastroenterol. 2017;70:96-102. [PMID: 28830135 DOI: 10.4166/kjg.2017.70.2.96] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
300 Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, Qu XJ. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol. 2014;12:171. [PMID: 24890327 DOI: 10.1186/1477-7819-12-171] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
301 Munkley J. The glycosylation landscape of pancreatic cancer. Oncol Lett 2019;17:2569-75. [PMID: 30854032 DOI: 10.3892/ol.2019.9885] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
302 Quan K, Sutera P, Xu K, Bernard ME, Burton SA, Wegner RE, Zeh H, Bahary N, Stoller R, Heron DE. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. Practical Radiation Oncology 2018;8:95-106. [DOI: 10.1016/j.prro.2017.10.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
303 Cen C, Liu L, Li X, Wu A, Liu H, Wang X, Wu H, Wang C, Han P, Wang S. Pancreatic Ductal Adenocarcinoma at CT: A Combined Nomogram Model to Preoperatively Predict Cancer Stage and Survival Outcome. Front Oncol 2021;11:594510. [PMID: 34109107 DOI: 10.3389/fonc.2021.594510] [Reference Citation Analysis]
304 Chen R, Crispin DA, Pan S, Hawley S, McIntosh MW, May D, Anton-Culver H, Ziogas A, Bronner MP, Brentnall TA. Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas. 2010;39:981-988. [PMID: 20467349 DOI: 10.1097/mpa.0b013e3181dac920] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
305 Olafsson S, Alexandersson KF, Gizurarson JGK, Hauksdottir K, Gunnarsson O, Olafsson K, Gudmundsson J, Stacey SN, Sveinbjornsson G, Saemundsdottir J, Bjornsson ES, Olafsson S, Bjornsson S, Orvar KB, Vikingsson A, Geirsson AJ, Arinbjarnarson S, Bjornsdottir G, Thorgeirsson TE, Sigurdsson S, Halldorsson GH, Magnusson OT, Masson G, Holm H, Jonsdottir I, Sigurdardottir O, Eyjolfsson GI, Olafsson I, Sulem P, Thorsteinsdottir U, Jonsson T, Rafnar T, Gudbjartsson DF, Stefansson K. Common and Rare Sequence Variants Influencing Tumor Biomarkers in Blood. Cancer Epidemiol Biomarkers Prev 2020;29:225-35. [PMID: 31666285 DOI: 10.1158/1055-9965.EPI-18-1060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
306 Khomiak A, Brunner M, Kordes M, Lindblad S, Miksch RC, Öhlund D, Regel I. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers (Basel) 2020;12:E3234. [PMID: 33147766 DOI: 10.3390/cancers12113234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
307 Zhu Y, Zhu Y, Cai F, Zhao J, Liu F. Prognostic Risk Factors Associated with Recurrence and Metastasis After Radical Resection in Patients with Hepatolithiasis Complicated by Intrahepatic Cholangiocarcinoma. Cell Biochem Biophys 2015;73:455-60. [DOI: 10.1007/s12013-015-0665-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
308 Prokopchuk O, Grünwald B, Nitsche U, Jäger C, Prokopchuk OL, Schubert EC, Friess H, Martignoni ME, Krüger A. Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer. BMC Cancer 2018;18:128. [PMID: 29394913 DOI: 10.1186/s12885-018-4055-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
309 Yu H, Son GM, Joh YG. The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer. J Korean Surg Soc. 2013;84:231-237. [PMID: 23577318 DOI: 10.4174/jkss.2013.84.4.231] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
310 Pan S, Brentnall TA, Chen R. Glycoproteins and glycoproteomics in pancreatic cancer. World J Gastroenterol. 2016;22:9288-9299. [PMID: 27895417 DOI: 10.3748/wjg.v22.i42.9288] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
311 Qu D, Johnson J, Chandrakesan P, Weygant N, May R, Aiello N, Rhim A, Zhao L, Zheng W, Lightfoot S, Pant S, Irvan J, Postier R, Hocker J, Hanas JS, Ali N, Sureban SM, An G, Schlosser MJ, Stanger B, Houchen CW. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells. PLoS One 2015;10:e0118933. [PMID: 25723399 DOI: 10.1371/journal.pone.0118933] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
312 Dumonceau JM, Delhaye M, Charette N, Farina A. Challenging biliary strictures: pathophysiological features, differential diagnosis, diagnostic algorithms, and new clinically relevant biomarkers - part 1.Therap Adv Gastroenterol. 2020;13:1756284820927292. [PMID: 32595761 DOI: 10.1177/1756284820927292] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
313 Xiao J, Lee WN, Zhao Y, Cao R, Go VL, Recker RR, Wang Q, Xiao GG. Profiling pancreatic cancer-secreted proteome using 15N amino acids and serum-free media. Pancreas 2010;39:e17-23. [PMID: 19904223 DOI: 10.1097/MPA.0b013e3181bc44dd] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
314 Zapico-Muñiz E, Farré-Viladrich A, Rico-Santana N, González-Sastre F, Mora-Brugués J. Standardized peptidome profiling of human serum for the detection of pancreatic cancer. Pancreas 2010;39:1293-8. [PMID: 20924310 DOI: 10.1097/MPA.0b013e3181dfcbe5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
315 Adamopoulos PG, Tsiakanikas P, Scorilas A. Kallikrein-related peptidases and associated microRNAs as promising prognostic biomarkers in gastrointestinal malignancies. Biological Chemistry 2018;399:821-36. [DOI: 10.1515/hsz-2017-0342] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
316 Yagyu T, Saito H, Sakamoto T, Uchinaka E, Morimoto M, Hanaki T, Watanabe J, Matsunaga T, Yamamoto M, Tokuyasu N, Honjo S, Fujiwara Y. Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer. BMC Surg 2021;21:8. [PMID: 33407353 DOI: 10.1186/s12893-020-00976-5] [Reference Citation Analysis]
317 Fliszkiewicz M, Niemczyk M, Kulesza A, Pączek L. Carbohydrate Antigen 19-9 Level in Patients with Autosomal Dominant Polycystic Kidney Disease. Transplant Proc 2018;50:1631-3. [PMID: 30056872 DOI: 10.1016/j.transproceed.2018.04.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
318 Klett H, Fuellgraf H, Levit-Zerdoun E, Hussung S, Kowar S, Küsters S, Bronsert P, Werner M, Wittel U, Fritsch R, Busch H, Boerries M. Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Front Genet 2018;9:108. [PMID: 29675033 DOI: 10.3389/fgene.2018.00108] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
319 Gordon BL, Finnerty BM, Aronova A, Fahey TJ. Genomic medicine for cancer diagnosis: Genomic Medicine for Cancer Diagnosis. J Surg Oncol 2015;111:24-30. [DOI: 10.1002/jso.23778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
320 Guardado NV, Llorente K, Blondeau B. Evaluation and Management of Malignant Biliary Obstruction. Surg Oncol Clin N Am 2021;30:491-503. [PMID: 34053664 DOI: 10.1016/j.soc.2021.03.001] [Reference Citation Analysis]
321 Rodrigues M, Richards N, Ning B, Lyon CJ, Hu TY. Rapid Lipid-Based Approach for Normalization of Quantum-Dot-Detected Biomarker Expression on Extracellular Vesicles in Complex Biological Samples. Nano Lett 2019;19:7623-31. [PMID: 31317745 DOI: 10.1021/acs.nanolett.9b02232] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
322 Swords DS, Firpo MA, Scaife CL, Mulvihill SJ. Biomarkers in pancreatic adenocarcinoma: current perspectives. Onco Targets Ther 2016;9:7459-67. [PMID: 28003762 DOI: 10.2147/OTT.S100510] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
323 Tong Y, Song Z, Zhu W. Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China. Clin Chem Lab Med 2013;51:1459-66. [PMID: 23492572 DOI: 10.1515/cclm-2012-0458] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
324 Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol 2017;39:101042831769223. [DOI: 10.1177/1010428317692231] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
325 Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas. 2013;42:193-197. [PMID: 23407481 DOI: 10.1097/mpa.0b013e31825e354d] [Cited by in Crossref: 61] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
326 Luo G, Guo M, Jin K, Liu Z, Liu C, Cheng H, Lu Y, Long J, Liu L, Xu J, Ni Q, Yu X. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping. Pancreatology 2016;16:1057-62. [DOI: 10.1016/j.pan.2016.09.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
327 Ray P, Rialon-Guevara KL, Veras E, Sullenger BA, White RR. Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. J Clin Invest 2012;122:1734-41. [PMID: 22484812 DOI: 10.1172/JCI62385] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
328 Bünger S, Laubert T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol. 2011;137:375-389. [PMID: 21193998 DOI: 10.1007/s00432-010-0965-x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
329 Grossman JG, Fields RC, Hawkins WG, Strasberg SM. Single institution results of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of pancreas in 78 patients. J Hepatobiliary Pancreat Sci. 2016;23:432-441. [PMID: 27207482 DOI: 10.1002/jhbp.362] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
330 Li H, Wang X, Fang Y, Huo Z, Lu X, Zhan X, Deng X, Peng C, Shen B. Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma. Oncotarget 2017;8:52571-83. [PMID: 28881752 DOI: 10.18632/oncotarget.16732] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
331 Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report. Cancer Biomark 2016;16:537-43. [PMID: 27002756 DOI: 10.3233/CBM-160595] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
332 Wagner PL, Austin F, Sathaiah M, Magge D, Maduekwe U, Ramalingam L, Jones HL, Holtzman MP, Ahrendt SA, Zureikat AH, Pingpank JF, Zeh HJ 3rd, Bartlett DL, Choudry HA. Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol 2013;20:506-14. [PMID: 22941175 DOI: 10.1245/s10434-012-2627-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
333 Kim J, Bamlet WR, Oberg AL, Chaffee KG, Donahue G, Cao XJ, Chari S, Garcia BA, Petersen GM, Zaret KS. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017;9. [PMID: 28701476 DOI: 10.1126/scitranslmed.aah5583] [Cited by in Crossref: 101] [Cited by in F6Publishing: 83] [Article Influence: 33.7] [Reference Citation Analysis]
334 Qi ZH, Xu HX, Zhang SR, Xu JZ, Li S, Gao HL, Jin W, Wang WQ, Wu CT, Ni QX, Yu XJ, Liu L. The Significance of Liquid Biopsy in Pancreatic Cancer. J Cancer 2018;9:3417-26. [PMID: 30271504 DOI: 10.7150/jca.24591] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
335 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
336 Al-Shamsi HO, Alzahrani M, Wolff RA. The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol 2016;7:E45-51. [PMID: 27284488 DOI: 10.21037/jgo.2016.01.05] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
337 Kim SB, Oh MJ, Lee SH. Gastric subepithelial lesion complicated with abscess: Case report and literature review. World J Gastroenterol 2015;21:6398-403. [PMID: 26034377 DOI: 10.3748/wjg.v21.i20.6398] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
338 Park JH, Choi EK, Ahn SD, Lee SW, Song SY, Yoon SM, Kim YS, Lee YS, Lee SG, Hwang S, Lee YJ, Park KM, Kim TW, Chang HM, Lee JL, Kim JH. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys. 2011;79:696-704. [PMID: 20510541 DOI: 10.1016/j.ijrobp.2009.12.031] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
339 Granger JH, Granger MC, Firpo MA, Mulvihill SJ, Porter MD. Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel. Analyst 2013;138:410-6. [PMID: 23150876 DOI: 10.1039/c2an36128k] [Cited by in Crossref: 61] [Cited by in F6Publishing: 9] [Article Influence: 8.7] [Reference Citation Analysis]
340 Hogendorf P, Durczyński A, Skulimowski A, Kumor A, Poznańska G, Strzelczyk J. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass. Cancer Biomark 2018;21:505-11. [PMID: 29171983 DOI: 10.3233/CBM-170203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
341 Makawita S, Smith C, Batruch I, Zheng Y, Rückert F, Grützmann R, Pilarsky C, Gallinger S, Diamandis EP. Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol Cell Proteomics 2011;10:M111.008599. [PMID: 21653254 DOI: 10.1074/mcp.M111.008599] [Cited by in Crossref: 78] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
342 Buscail E, Chauvet A, Quincy P, Degrandi O, Buscail C, Lamrissi I, Moranvillier I, Caumont C, Verdon S, Brisson A, Marty M, Chiche L, Laurent C, Vendrely V, Moreau-Gaudry F, Bedel A, Dabernat S. CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. Transl Oncol 2019;12:1395-403. [PMID: 31400579 DOI: 10.1016/j.tranon.2019.07.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
343 Heiler S, Wang Z, Zöller M. Pancreatic cancer stem cell markers and exosomes - the incentive push. World J Gastroenterol 2016;22:5971-6007. [PMID: 27468191 DOI: 10.3748/wjg.v22.i26.5971] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 43] [Article Influence: 12.0] [Reference Citation Analysis]
344 Shi C, Merchant N, Newsome G, Goldenberg DM, Gold DV. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Arch Pathol Lab Med. 2014;138:220-228. [PMID: 24476519 DOI: 10.5858/arpa.2013-0056-oa] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
345 Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for pancreatic cancer: why, how, and who? Ann Surg 2013;257:17-26. [PMID: 22895395 DOI: 10.1097/SLA.0b013e31825ffbfb] [Cited by in Crossref: 120] [Cited by in F6Publishing: 59] [Article Influence: 15.0] [Reference Citation Analysis]
346 Yang F, Yang Z, Zhuo Y, Chai Y, Yuan R. Ultrasensitive electrochemical immunosensor for carbohydrate antigen 19-9 using Au/porous graphene nanocomposites as platform and Au@Pd core/shell bimetallic functionalized graphene nanocomposites as signal enhancers. Biosensors and Bioelectronics 2015;66:356-62. [DOI: 10.1016/j.bios.2014.10.066] [Cited by in Crossref: 67] [Cited by in F6Publishing: 53] [Article Influence: 11.2] [Reference Citation Analysis]
347 Park J, Lee E, Park KJ, Park HD, Kim JW, Woo HI, Lee KH, Lee KT, Lee JK, Park JO, Park YS, Heo JS, Choi SH, Choi DW, Jang KT, Lee SY. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. Oncotarget 2017;8:42761-71. [PMID: 28514751 DOI: 10.18632/oncotarget.17463] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
348 Lee MJ, Na K, Jeong SK, Lim JS, Kim SA, Lee MJ, Song SY, Kim H, Hancock WS, Paik YK. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma. J Proteome Res 2014;13:4878-88. [PMID: 25057901 DOI: 10.1021/pr5002719] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
349 Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015;15:797. [PMID: 26498594 DOI: 10.1186/s12885-015-1779-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 88] [Article Influence: 16.3] [Reference Citation Analysis]
350 Guo A, Li Y, Cao W, Meng X, Wu D, Wei Q, Du B. An electrochemical immunosensor for ultrasensitive detection of carbohydrate antigen 199 based on Au@Cu(x)OS yolk-shell nanostructures with porous shells as labels. Biosens Bioelectron 2015;63:39-46. [PMID: 25058937 DOI: 10.1016/j.bios.2014.07.017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 6.9] [Reference Citation Analysis]
351 Xiong Y, Shi C, Zhong F, Liu X, Yang P. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer. Clin Chim Acta 2020;506:214-21. [PMID: 32243985 DOI: 10.1016/j.cca.2020.03.043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
352 Utomo WK, Looijenga LH, Bruno MJ, Hansen BE, Gillis A, Biermann K, Peppelenbosch MP, Fuhler GM, Braat H. A MicroRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective Cohort. Mol Ther Nucleic Acids. 2016;5:e350. [PMID: 28131248 DOI: 10.1038/mtna.2016.61] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
353 Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med 2013;54:1876-82. [PMID: 24029655 DOI: 10.2967/jnumed.113.119867] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
354 Słotwiński R, Słotwińska SM. Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer. Cent Eur J Immunol 2016;41:392-403. [PMID: 28450803 DOI: 10.5114/ceji.2016.65139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
355 Ibáñez-redín G, Furuta RH, Wilson D, Shimizu FM, Materon EM, Arantes LMRB, Melendez ME, Carvalho AL, Reis RM, Chaur MN, Gonçalves D, Oliveira Jr ON. Screen-printed interdigitated electrodes modified with nanostructured carbon nano-onion films for detecting the cancer biomarker CA19-9. Materials Science and Engineering: C 2019;99:1502-8. [DOI: 10.1016/j.msec.2019.02.065] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
356 Muirhead LJ, Kinross J, FitzMaurice TS, Takats Z, Darzi A, Nicholson JK. Surgical systems biology and personalized longitudinal phenotyping in critical care. Per Med 2012;9:593-608. [PMID: 29768802 DOI: 10.2217/pme.12.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
357 Zhou W, Wang D, Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control 2020;27:1073274820976593. [PMID: 33238715 DOI: 10.1177/1073274820976593] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
358 Kim HJ, Lee KW, Kim YJ, Oh DY, Kim JH, Im SA, Lee JS. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncol. 2009;48:385-390. [PMID: 18855156 DOI: 10.1080/02841860802446761] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
359 Scarà S, Bottoni P, Scatena R. CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol 2015;867:247-60. [PMID: 26530370 DOI: 10.1007/978-94-017-7215-0_15] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 19.8] [Reference Citation Analysis]
360 Natale F, Vivo M, Falco G, Angrisano T. Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis. Clin Epigenetics. 2019;11:132. [PMID: 31492175 DOI: 10.1186/s13148-019-0728-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
361 Pombeiro I, Loosen SH, Roy S, Schueller F, Niewenhuisen L, Luedde M, Vucur M, Tacke F, Binnebösel M, Schoening W, Trautwein C, Luedde T, Neumann UP, Roderburg C. Differential Roles of Tumor Necrosis Factor Ligand Superfamily Members as Biomarkers in Pancreatic Cancer. J Clin Med 2018;7:E175. [PMID: 30011858 DOI: 10.3390/jcm7070175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
362 Scarpa M, Noaro G, Saadeh L, Cavallin F, Cagol M, Alfieri R, Plebani M, Castoro C. Esophageal cancer management: preoperative CA19.9 and CEA serum levels may identify occult advanced adenocarcinoma. World J Surg. 2015;39:424-432. [PMID: 25326423 DOI: 10.1007/s00268-014-2835-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
363 Zhao C, Gao F, Weng S, Liu Q. Pancreatic cancer and associated exosomes. Cancer Biomark. 2017;20:357-367. [PMID: 29036786 DOI: 10.3233/cbm-170258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
364 Yilmaz B, Roach EC, Koklu S. An Unusual Cause of a High Carbonhydrate Antigen 19-9 Level in an Elderly Individual: Polycystic Liver Disease. J Am Geriatr Soc 2015;63:1487-8. [DOI: 10.1111/jgs.13541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
365 Tang H, Hsueh P, Kletter D, Bern M, Haab B. The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities. Adv Cancer Res 2015;126:167-202. [PMID: 25727148 DOI: 10.1016/bs.acr.2014.11.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
366 Felix K, Hinz U, Dobiasch S, Hackert T, Bergmann F, Neumüller M, Gronowitz S, Bergqvist M, Strobel O. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer. Pancreas 2018;47:72-9. [PMID: 29189449 DOI: 10.1097/MPA.0000000000000966] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
367 Lin C, Wu WC, Zhao GC, Wang DS, Lou WH, Jin DY. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2016;95:e4527. [PMID: 27495108 DOI: 10.1097/MD.0000000000004527] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
368 Huang X, Hong C, Peng Y, Yang S, Huang L, Liu C, Chen L, Chu L, Xu L, Xu Y. The Diagnostic Value of Serum IGFBP7 in Patients with Esophageal Squamous Cell Carcinoma. J Cancer 2019;10:2687-93. [PMID: 31258777 DOI: 10.7150/jca.32393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
369 Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y, Qian Y, Huang Q, Ni Q, Liu C, Yu X. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 2021;1875:188409. [PMID: 32827580 DOI: 10.1016/j.bbcan.2020.188409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
370 Jimenez-Luna C, Torres C, Ortiz R, Dieguez C, Martinez-Galan J, Melguizo C, Prados JC, Caba O. Proteomic biomarkers in body fluids associated with pancreatic cancer. Oncotarget. 2018;9:16573-16587. [PMID: 29662668 DOI: 10.18632/oncotarget.24654] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
371 Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, Diamandis EP. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. BMC Cancer. 2013;13:404. [PMID: 24007603 DOI: 10.1186/1471-2407-13-404] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
372 Ward DG, Wei W, Buckels J, Taha AM, Hegab B, Tariciotti L, Salih R, Qi YQ, Martin A, Johnson PJ. Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen. Eur J Gastroenterol Hepatol 2010;22:1358-63. [PMID: 20555269 DOI: 10.1097/MEG.0b013e32833b6d41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
373 Parikh DA, Durbin-Johnson B, Urayama S. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population. J Gastrointest Cancer 2014;45:74-9. [PMID: 24272911 DOI: 10.1007/s12029-013-9563-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
374 Matsuda A, Kuno A, Nakagawa T, Ikehara Y, Irimura T, Yamamoto M, Nakanuma Y, Miyoshi E, Nakamori S, Nakanishi H, Viwatthanasittiphong C, Srivatanakul P, Miwa M, Shoda J, Narimatsu H. Lectin Microarray-Based Sero-Biomarker Verification Targeting Aberrant O-Linked Glycosylation on Mucin 1. Anal Chem 2015;87:7274-81. [PMID: 26091356 DOI: 10.1021/acs.analchem.5b01329] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
375 Tang H, Partyka K, Hsueh P, Sinha JY, Kletter D, Zeh H, Huang Y, Brand RE, Haab BB. Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. Cell Mol Gastroenterol Hepatol. 2016;2:201-221.e15. [PMID: 26998508 DOI: 10.1016/j.jcmgh.2015.12.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
376 Padoan A, Seraglia R, Basso D, Fogar P, Sperti C, Moz S, Greco E, Marchet A, de Manzoni G, Zambon C, Navaglia F, Cristadoro L, Di Chiara A, Nitti D, Pedrazzoli S, Pavanello G, Plebani M. Usefulness of MALDI-TOF/MS Identification of Low-MW Fragments in Sera for the Differential Diagnosis of Pancreatic Cancer. Pancreas 2013;42:622-32. [DOI: 10.1097/mpa.0b013e318273096c] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
377 Binicier OB, Pakoz ZB. CA 19-9 levels in patients with acute pancreatitis due to gallstone and metabolic/toxic reasons. Rev Assoc Med Bras (1992). 2019;65:965-970. [PMID: 31389506 DOI: 10.1590/1806-9282.65.7.965] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
378 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
379 Piagnerelli R, Marrelli D, Roviello G, Ferrara F, Di Mare G, Voglino C, Petrioli R, Marini M, Macchiarelli R, Roviello F. Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas. Tumour Biol 2016;37:1959-66. [PMID: 26334620 DOI: 10.1007/s13277-015-3986-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
380 van der Kaaij RT, Voncken FEM, van Dieren JM, Snaebjornsson P, Korse CM, Grootscholten C, Aleman BMP, van Sandick JW. Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma. Am J Clin Oncol 2019;42:345-50. [PMID: 30724779 DOI: 10.1097/COC.0000000000000525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
381 Srisuttee R, Ota J, Muangsub T, Keelawat S, Trirattanachat S, Kitkumthorn N, Mutirangura A. FRY site-specific methylation differentiates pancreatic ductal adenocarcinoma from other adenocarcinomas. APMIS 2016;124:469-74. [PMID: 26990916 DOI: 10.1111/apm.12527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
382 Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E, Roviello F. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009;198:333-339. [PMID: 19375064 DOI: 10.1016/j.amjsurg.2008.12.031] [Cited by in Crossref: 120] [Cited by in F6Publishing: 100] [Article Influence: 10.0] [Reference Citation Analysis]
383 van Manen L, Groen JV, Putter H, Vahrmeijer AL, Swijnenburg RJ, Bonsing BA, Mieog JSD. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Biomarkers. 2020;25:186-193. [PMID: 32009482 DOI: 10.1080/1354750x.2020.1725786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
384 Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol. 2012;33:799-807. [PMID: 22203495 DOI: 10.1007/s13277-011-0297-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
385 Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, Chan DW, Zhang Z. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev 2019;28:174-82. [PMID: 30333219 DOI: 10.1158/1055-9965.EPI-18-0483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
386 Lwin TM, Hoffman RM, Bouvet M. The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic. Expert Rev Anticancer Ther 2018;18:651-62. [PMID: 29768067 DOI: 10.1080/14737140.2018.1477593] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
387 Kosanam H, Makawita S, Judd B, Newman A, Diamandis EP. Mining the malignant ascites proteome for pancreatic cancer biomarkers. Proteomics 2011;11:4551-8. [PMID: 21932441 DOI: 10.1002/pmic.201100264] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
388 Coleman O, Henry M, O'Neill F, Roche S, Swan N, Boyle L, Murphy J, Meiller J, Conlon NT, Geoghegan J, Conlon KC, Lynch V, Straubinger NL, Straubinger RM, McVey G, Moriarty M, Meleady P, Clynes M. A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts. Proteomes 2018;6:45. [PMID: 30404163 DOI: 10.3390/proteomes6040045] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
389 Loosen SH, Vucur M, Trautwein C, Roderburg C, Luedde T. Circulating Biomarkers for Cholangiocarcinoma. Dig Dis 2018;36:281-8. [PMID: 29807369 DOI: 10.1159/000488342] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
390 Fukasawa H, Kaneko M, Niwa H, Yasuda H, Kumagai H, Furuya R. Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease. Nephrology (Carlton). 2018;23:210-216. [PMID: 28024168 DOI: 10.1111/nep.12988] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
391 Shi S, Yu X. Selecting chemotherapy for pancreatic cancer: Far away or so close? Semin Oncol 2019;46:39-47. [PMID: 30611527 DOI: 10.1053/j.seminoncol.2018.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
392 Nuzhat Z, Kinhal V, Sharma S, Rice GE, Joshi V, Salomon C. Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression. Oncotarget 2017;8:17279-91. [PMID: 27999198 DOI: 10.18632/oncotarget.13973] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 11.8] [Reference Citation Analysis]
393 Xie C, Aloreidi K, Patel B, Ridgway T, Thambi-Pillai T, Timmerman G, Khan A, Atiq M. Indeterminate biliary strictures: a simplified approach. Expert Rev Gastroenterol Hepatol. 2018;12:189-199. [PMID: 29034764 DOI: 10.1080/17474124.2018.1391090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
394 van Heerde MJ, Buijs J, Hansen BE, de Waart M, van Eijck CHJ, Kazemier G, Pek CJ, Poley JW, Bruno MJ, Kuipers EJ, van Buuren HR. Serum Level of Ca 19-9 Increases Ability of IgG4 Test to Distinguish Patients with Autoimmune Pancreatitis from Those with Pancreatic Carcinoma. Dig Dis Sci. [DOI: 10.1007/s10620-013-3004-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
395 Karatolios K, Pankuweit S, Maisch B. Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion. Heart Fail Rev 2013;18:337-44. [PMID: 22638889 DOI: 10.1007/s10741-012-9327-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
396 Chen J, Wu W, Zhen C, Zhou H, Yang R, Chen L, Hu L. Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer. Oncol Lett 2013;6:43-8. [PMID: 23946775 DOI: 10.3892/ol.2013.1326] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
397 Sielaff CM, Mousa SA. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. J Cancer Res Clin Oncol 2018;144:1205-17. [PMID: 29721665 DOI: 10.1007/s00432-018-2651-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
398 Talar-Wojnarowska R, Gasiorowska A, Olakowski M, Lekstan A, Lampe P, Malecka-Panas E. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis. Pancreatology 2010;10:689-94. [PMID: 21242708 DOI: 10.1159/000320693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
399 Saukkonen K, Hagström J, Mustonen H, Lehtinen L, Carpen O, Andersson LC, Seppänen H, Haglund C. Prognostic and diagnostic value of REG4 serum and tissue expression in pancreatic ductal adenocarcinoma. Tumour Biol 2018;40:1010428318761494. [PMID: 29542402 DOI: 10.1177/1010428318761494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
400 Chen J, Wu W, Chen L, Zhou H, Yang R, Hu L, Zhao Y. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein. Pancreatology 2013;13:290-7. [PMID: 23719603 DOI: 10.1016/j.pan.2013.03.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
401 Nolen BM, Lokshin AE. -The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid. Int J Biol Markers 2011;26:141-52. [PMID: 21928247 DOI: 10.5301/JBM.2011.8613] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
402 Choi YJ, Yoon W, Lee A, Han Y, Byun Y, Kang JS, Kim H, Kwon W, Suh YA, Kim Y, Lee S, Namkung J, Han S, Choi Y, Heo JS, Park JO, Park JK, Kim SC, Kang CM, Lee WJ, Park T, Jang JY. Diagnostic model for pancreatic cancer using a multi-biomarker panel. Ann Surg Treat Res 2021;100:144-53. [PMID: 33748028 DOI: 10.4174/astr.2021.100.3.144] [Reference Citation Analysis]
403 Passerini R, Cassatella MC, Boveri S, Salvatici M, Radice D, Zorzino L, Galli C, Sandri MT. The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center. Am J Clin Pathol 2012;138:281-7. [PMID: 22904141 DOI: 10.1309/AJCPOPNPLLCYR07H] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
404 Tacke F, Kanig N, En-Nia A, Kaehne T, Eberhardt CS, Shpacovitch V, Trautwein C, Mertens PR. Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. BMC Cancer 2011;11:185. [PMID: 21595987 DOI: 10.1186/1471-2407-11-185] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
405 Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, Kleiß M, Leha A, Ghadimi M, Gaedcke J. CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep 2020;10:1332. [PMID: 31992753 DOI: 10.1038/s41598-020-57930-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
406 Wojtalewicz N, Sadeqzadeh E, Weiß JV, Tehrani MM, Klein-Scory S, Hahn S, Schmiegel W, Warnken U, Schnölzer M, de Bock CE, Thorne RF, Schwarte-Waldhoff I. A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding. PLoS One 2014;9:e90461. [PMID: 24625754 DOI: 10.1371/journal.pone.0090461] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
407 Corbo V, Tortora G, Scarpa A. Molecular pathology of pancreatic cancer: from bench-to-bedside translation. Curr Drug Targets. 2012;13:744-752. [PMID: 22458520 DOI: 10.2174/138945012800564103] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
408 Brancaccio M, Natale F, Falco G, Angrisano T. Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery. Genes (Basel) 2019;11:E14. [PMID: 31877923 DOI: 10.3390/genes11010014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
409 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021] [Cited by in F6Publishing: 207] [Reference Citation Analysis]
410 Pan S, Chen R, Tamura Y, Crispin DA, Lai LA, May DH, McIntosh MW, Goodlett DR, Brentnall TA. Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma. J Proteome Res. 2014;13:1293-1306. [PMID: 24471499 DOI: 10.1021/pr4010184] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
411 Muniraj T, Chari ST. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol. 2012;58:331-345. [PMID: 23207610 DOI: 10.6092/1590-8577/2286] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
412 Ge L, Pan B, Song F, Ma J, Zeraatkar D, Zhou J, Tian J. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open 2017;7:e018175. [PMID: 29282264 DOI: 10.1136/bmjopen-2017-018175] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
413 Liu X, Zheng W, Wang W, Shen H, Liu L, Lou W, Wang X, Yang P. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline. Br J Cancer. 2017;117:1846-1854. [PMID: 29123261 DOI: 10.1038/bjc.2017.365] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]